# Raymond P. Ward proposes the following substitute bill:

1

## **Medical Cannabis Modifications**

# 2025 GENERAL SESSION STATE OF UTAH

Chief Sponsor: Raymond P. Ward

Senate Sponsor: Luz Escamilla

2

5

#### LONG TITLE

### **4** General Description:

This bill amends provisions related to medical cannabis.

# **6 Highlighted Provisions:**

- 7 This bill:
- 8 repeals provisions related to qualified medical providers and limited medical providers in
- 9 the medical cannabis program;
- 10 allows certain health care providers to recommend medical cannabis without first
- registering with the Department of Health and Human Services;
- repeals continuing education requirements related to medical cannabis;
- 13 moves enforcement of advertising and payment requirements related to medical cannabis
- 14 from the Department of Health and Human Services to the Division of Professional
- 15 Licensing; and
  - makes technical and conforming changes.

#### 17 Money Appropriated in this Bill:

None None

- 19 Other Special Clauses:
- This bill provides a special effective date.
- 21 Utah Code Sections Affected:
- 22 AMENDS:
- **4-41a-102**, as last amended by Laws of Utah 2024, Chapters 217, 238 and 240
- 24 **4-41a-301**, as last amended by Laws of Utah 2024, Chapter 217
- 25 **4-41a-602**, as last amended by Laws of Utah 2024, Chapter 217
- 26 **4-41a-1101**, as last amended by Laws of Utah 2024, Chapter 217
- 27 **26B-1-435**, as last amended by Laws of Utah 2024, Chapters 238, 240
- 28 **26B-2-203**, as renumbered and amended by Laws of Utah 2023, Chapter 305

- 29 **26B-4-201**, as last amended by Laws of Utah 2024, Chapters 217, 240 30 **26B-4-202**, as last amended by Laws of Utah 2024, Chapters 217, 240 31 26B-4-203, as last amended by Laws of Utah 2023, Chapter 317 and renumbered and 32 amended by Laws of Utah 2023, Chapter 307 26B-4-204, as last amended by Laws of Utah 2024, Chapter 217 33 34 **26B-4-205**, as renumbered and amended by Laws of Utah 2023, Chapter 307 35 **26B-4-213**, as last amended by Laws of Utah 2024, Chapters 217, 240 36 **26B-4-214**, as last amended by Laws of Utah 2024, Chapter 240 26B-4-231, as last amended by Laws of Utah 2024, Chapter 238 37 38 **26B-4-245**, as last amended by Laws of Utah 2024, Chapters 217, 240 **53B-17-903**, as last amended by Laws of Utah 2023, Chapter 328 39 40 **58-5a-102**, as last amended by Laws of Utah 2024, Chapter 458 41 **58-31b-305**, as last amended by Laws of Utah 2023, Chapter 329 42 **58-31b-502**, as last amended by Laws of Utah 2024, Chapter 237 43 **58-67-304**, as last amended by Laws of Utah 2023, Chapters 301, 329 44 **58-67-502**, as last amended by Laws of Utah 2024, Chapter 237 45 **58-68-304**, as last amended by Laws of Utah 2023, Chapters 301, 329 46 **58-68-502**, as last amended by Laws of Utah 2024, Chapter 237 47 **58-70a-303**, as last amended by Laws of Utah 2023, Chapter 329 48 **58-70a-503**, as last amended by Laws of Utah 2024, Chapter 237 49 **80-4-109**, as last amended by Laws of Utah 2023, Chapters 273, 317 and 330 and last 50 amended by Coordination Clause, Laws of Utah 2023, Chapter 330 51 **ENACTS**: 52 **58-1-513**, Utah Code Annotated 1953 53 54 *Be it enacted by the Legislature of the state of Utah:* 55 Section 1. Section **4-41a-102** is amended to read: 4-41a-102. Definitions. 56 57 As used in this chapter: 58 (1) "Adulterant" means any poisonous or deleterious substance in a quantity that may be
  - (c) solvents;

(a) pesticides;

(b) heavy metals;

injurious to health, including:

59

60

61

63	(d) microbial life;
64	(e) artificially derived cannabinoid;
65	(f) toxins; or
66	(g) foreign matter.
67	(2) "Advertise" or "advertising" means information provided by a person in any medium:
68	(a) to the public; and
69	(b) that is not age restricted to an individual who is at least 21 years old.
70	(3) "Advisory board" means the Medical Cannabis Policy Advisory Board created in
71	Section 26B-1-435.
72	(4)(a) "Anticompetitive business practice" means any practice that reduces the amount
73	of competition in the medical cannabis market that would be considered an attempt to
74	monopolize, as defined in Section 76-10-3103.
75	(b) "Anticompetitive business practice" may include:
76	(i) agreements that may be considered unreasonable when competitors interact to the
77	extent that they are:
78	(A) no longer acting independently; or
79	(B) when collaborating are able to wield market power together;
80	(ii) monopolizing or attempting to monopolize trade by:
81	(A) acting to maintain or acquire a dominant position in the market; or
82	(B) preventing new entry into the market; or
83	(iii) other conduct outlined in rule.
84	(5)(a) "Artificially derived cannabinoid" means a chemical substance that is created by a
85	chemical reaction that changes the molecular structure of any chemical substance
86	derived from the cannabis plant.
87	(b) "Artificially derived cannabinoid" does not include:
88	(i) a naturally occurring chemical substance that is separated from the cannabis plant
89	by a chemical or mechanical extraction process; or
90	(ii) a cannabinoid that is produced by decarboxylation from a naturally occurring
91	cannabinoid acid without the use of a chemical catalyst.
92	(6) "Cannabis Research Review Board" means the Cannabis Research Review Board
93	created in Section 26B-1-420.
94	(7) "Cannabis" means the same as that term is defined in Section 26B-4-201.
95	(8) "Cannabis concentrate" means:
96	(a) the product of any chemical or physical process applied to naturally occurring

97 biomass that concentrates or isolates the cannabinoids contained in the biomass; and 98 (b) any amount of a natural cannabinoid or artificially derived cannabinoid in an 99 artificially derived cannabinoid's purified state. 100 (9) "Cannabis cultivation byproduct" means any portion of a cannabis plant that is not 101 intended to be sold as a cannabis plant product. 102 (10) "Cannabis cultivation facility" means a person that: 103 (a) possesses cannabis; 104 (b) grows or intends to grow cannabis; and 105 (c) sells or intends to sell cannabis to a cannabis cultivation facility, a cannabis 106 processing facility, or a medical cannabis research licensee. 107 (11) "Cannabis cultivation facility agent" means an individual who 108 holds a valid cannabis production establishment agent registration card with a cannabis 109 cultivation facility designation. 110 (12) "Cannabis derivative product" means a product made using cannabis concentrate. 111 (13) "Cannabis plant product" means any portion of a cannabis plant intended to be sold in 112 a form that is recognizable as a portion of a cannabis plant. 113 (14) "Cannabis processing facility" means a person that: 114 (a) acquires or intends to acquire cannabis from a cannabis production establishment; 115 (b) possesses cannabis with the intent to manufacture a cannabis product; 116 (c) manufactures or intends to manufacture a cannabis product from unprocessed 117 cannabis or a cannabis extract; and (d) sells or intends to sell a cannabis product to a medical cannabis pharmacy or a 118 119 medical cannabis research licensee. 120 (15) "Cannabis processing facility agent" means an individual who 121 holds a valid cannabis production establishment agent registration card with a cannabis 122 processing facility designation. 123 (16) "Cannabis product" means the same as that term is defined in Section 26B-4-201. 124 (17) "Cannabis production establishment" means a cannabis cultivation facility, a cannabis 125 processing facility, or an independent cannabis testing laboratory. 126 (18) "Cannabis production establishment agent" means a cannabis cultivation facility agent, 127 a cannabis processing facility agent, or an independent cannabis testing laboratory agent. 128 (19) "Cannabis production establishment agent registration card" means a registration card 129 that the department issues that: 130 (a) authorizes an individual to act as a cannabis production establishment agent; and

131	(b) designates the type of cannabis production establishment for which an individual is
132	authorized to act as an agent.
133	(20) "Closed-door medical cannabis pharmacy" means a facility operated by a home
134	delivery medical cannabis pharmacy for delivering cannabis or a medical cannabis
135	product.
136	(21) "Community location" means a public or private elementary or secondary school, a
137	church, a public library, a public playground, or a public park.
138	(22) "Cultivation space" means, quantified in square feet, the horizontal area in which a
139	cannabis cultivation facility cultivates cannabis, including each level of horizontal area
140	if the cannabis cultivation facility hangs, suspends, stacks, or otherwise positions plants
141	above other plants in multiple levels.
142	(23) "Delivery address" means:
143	(a) for a medical cannabis cardholder who is not a facility:
144	(i) the medical cannabis cardholder's home address; or
145	(ii) an address designated by the medical cannabis cardholder that:
146	(A) is the medical cannabis cardholder's workplace; and
147	(B) is not a community location; or
148	(b) for a medical cannabis cardholder that is a facility, the facility's address.
149	(24) "Department" means the Department of Agriculture and Food.
150	(25) "Family member" means a parent, step-parent, spouse, child, sibling, step-sibling,
151	uncle, aunt, nephew, niece, first cousin, mother-in-law, father-in-law, brother-in-law,
152	sister-in-law, son-in-law, daughter-in-law, grandparent, or grandchild.
153	(26) "Government issued photo identification" means the same as that term is defined in
154	Section 26B-4-201, including expired identification in accordance with Section
155	26B-4-244.
156	(27) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy that
157	the department authorizes, as part of the pharmacy's license, to deliver medical cannabis
158	shipments to a delivery address to fulfill electronic orders that the state central patient
159	portal facilitates.
160	(28)(a) "Independent cannabis testing laboratory" means a person that:
161	(i) conducts a chemical or other analysis of cannabis or a cannabis product; or
162	(ii) acquires, possesses, and transports cannabis or a cannabis product with the intent
163	to conduct a chemical or other analysis of the cannabis or cannabis product.
164	(b) "Independent cannabis testing laboratory" includes a laboratory that the department

- or a research university operates in accordance with Subsection 4-41a-201(14).
- 166 (29) "Independent cannabis testing laboratory agent" means an individual who
- holds a valid cannabis production establishment agent registration card with an
- independent cannabis testing laboratory designation.
- 169 (30) "Inventory control system" means a system described in Section 4-41a-103.
- 170 (31) "Licensing board" or "board" means the Cannabis Production Establishment and
- Pharmacy Licensing Advisory Board created in Section 4-41a-201.1.
- 172 (32) "Medical cannabis" means the same as that term is defined in Section 26B-4-201.
- 173 (33) "Medical cannabis card" means the same as that term is defined in Section 26B-4-201.
- 174 (34) "Medical cannabis courier" means a courier that:
- (a) the department licenses in accordance with Section 4-41a-1201; and
- (b) contracts with a home delivery medical cannabis pharmacy to deliver medical
- cannabis shipments to fulfill electronic orders that the state central patient portal
- facilitates.
- 179 (35) "Medical cannabis courier agent" means an individual who:
- (a) is an employee of a medical cannabis courier; and
- (b) who holds a valid medical cannabis courier agent registration card.
- 182 (36) "Medical cannabis pharmacy" means the same as that term is defined in Section
- 183 26B-4-201.
- 184 (37) "Medical cannabis pharmacy agent" means the same as that term is defined in Section
- 185 26B-4-201.
- 186 (38) "Medical cannabis research license" means a license that the department issues to a
- research university for the purpose of obtaining and possessing medical cannabis for
- academic research.
- 189 (39) "Medical cannabis research licensee" means a research university that the department
- licenses to obtain and possess medical cannabis for academic research, in accordance
- 191 with Section 4-41a-901.
- 192 (40) "Medical cannabis shipment" means a shipment of medical cannabis that a home
- delivery medical cannabis pharmacy or a medical cannabis courier delivers to a delivery
- address to fulfill an electronic medical cannabis order that the state central patient portal
- facilitates.
- 196 (41) "Medical cannabis treatment" means the same as that term is defined in Section
- 197 26B-4-201.
- 198 (42) "Medicinal dosage form" means the same as that term is defined in Section 26B-4-201.

199	(43) "Pharmacy ownership limit" means an amount equal to 30% of the total number of
200	medical cannabis pharmacy licenses issued by the department rounded down to the
201	nearest whole number.
202	(44) "Pharmacy medical provider" means the same as that term is defined in Section
203	26B-4-201.
204	[(45) "Qualified medical provider" means the same as that term is defined in Section
205	<del>26B-4-201.</del> ]
206	[(46)] (45) "Qualified Production Enterprise Fund" means the fund created in Section
207	4-41a-104.
208	[(47)] (46) "Recommending medical provider" means the same as that term is defined in
209	Section 26B-4-201.
210	[(48)] (47) "Research university" means the same as that term is defined in Section
211	53B-7-702 and a private, nonprofit college or university in the state that:
212	(a) is accredited by the Northwest Commission on Colleges and Universities;
213	(b) grants doctoral degrees; and
214	(c) has a laboratory containing or a program researching a schedule I controlled
215	substance described in Section 58-37-4.
216	[(49)] (48) "State electronic verification system" means the system described in Section
217	26B-4-202.
218	[(50)] (49) "Targeted marketing" means the promotion of a cannabis product, medical
219	cannabis brand, or a medical cannabis device using any of the following methods:
220	(a) electronic communication to an individual who is at least 21 years old and has
221	requested to receive promotional information;
222	(b) an in-person marketing event that is:
223	(i) held inside a medical cannabis pharmacy; and
224	(ii) in an area where only a medical cannabis cardholder may access the event;
225	(c) other marketing material that is physically available or digitally displayed in a
226	medical cannabis pharmacy; or
227	(d) a leaflet a medical cannabis pharmacy places in the opaque package or box that is
228	provided to an individual when obtaining medical cannabis:
229	(i) in the medical cannabis pharmacy;
230	(ii) at the medical cannabis pharmacy's drive-through pick up window; or
231	(iii) in a medical cannabis shipment.
232	[(51)] (50) "Tetrahydrocannabinol" or "THC" means the same as that term is defined in

233	Section 4-41-102.
234	[(52)] (51) "THC analog" means the same as that term is defined in Section 4-41-102.
235	[(53)] (52) "Total composite tetrahydrocannabinol" means all detectable forms of
236	tetrahydrocannabinol.
237	[(54)] (53) "Total tetrahydrocannabinol" or "total THC" means the same as that term is
238	defined in Section 4-41-102.
239	Section 2. Section <b>4-41a-301</b> is amended to read:
240	4-41a-301. Cannabis production establishment agent Registration.
241	(1) An individual may not act as a cannabis production establishment agent unless the
242	department registers the individual as a cannabis production establishment agent,
243	regardless of whether the individual is a seasonal, temporary, or permanent employee.
244	(2) The following individuals, regardless of the individual's status as a [qualified medical
245	provider] recommending medical provider, may not serve as a cannabis production
246	establishment agent, have a financial or voting interest of 2% or greater in a cannabis
247	production establishment, or have the power to direct or cause the management or
248	control of a cannabis production establishment:
249	(a) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;
250	(b) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse
251	Practice Act;
252	(c) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title
253	58, Chapter 68, Utah Osteopathic Medical Practice Act; or
254	(d) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician Assistan
255	Act.
256	(3) An independent cannabis testing laboratory agent may not act as an agent for a medical
257	cannabis pharmacy, a medical cannabis courier, a cannabis processing facility, or a
258	cannabis cultivation facility.
259	(4)(a) The department shall, within 15 business days after the day on which the
260	department receives a complete application from a prospective cannabis production
261	establishment agent, register and issue a cannabis production establishment agent
262	registration card to the prospective agent if the prospective agent:
263	(i) provides to the department:
264	(A) the prospective agent's name and address;
265	(B) which cannabis production establishment agent designations the applicant
266	desires; and

267		(C) the submission required under Subsection (4)(b); and
268		(ii) pays a fee to the department in an amount that, subject to Subsection 4-41a-104
269		(5), the department sets in accordance with Section 63J-1-504.
270	(b)	Each prospective agent described in Subsection (4)(a) shall:
271		(i) submit to the department:
272		(A) a fingerprint card in a form acceptable to the Department of Public Safety; and
273		(B) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging
274		the registration of the prospective agent's fingerprints in the Federal Bureau of
275		Investigation Next Generation Identification System's Rap Back Service; and
276		(ii) consent to a fingerprint background check by:
277		(A) the Bureau of Criminal Identification; and
278		(B) the Federal Bureau of Investigation.
279	(c)	The Bureau of Criminal Identification shall:
280		(i) check the fingerprints the prospective agent submits under Subsection (4)(b)
281		against the applicable state, regional, and national criminal records databases,
282		including the Federal Bureau of Investigation Next Generation Identification
283		System;
284		(ii) report the results of the background check to the department;
285		(iii) maintain a separate file of fingerprints that prospective agents submit under
286		Subsection (4)(b) for search by future submissions to the local and regional
287		criminal records databases, including latent prints;
288		(iv) request that the fingerprints be retained in the Federal Bureau of Investigation
289		Next Generation Identification System's Rap Back Service for search by future
290		submissions to national criminal records databases, including the Next Generation
291		Identification System and latent prints; and
292		(v) establish a privacy risk mitigation strategy to ensure that the department only
293		receives notifications for an individual with whom the department maintains an
294		authorizing relationship.
295	(d)	The department shall:
296		(i) assess an individual who submits fingerprints under Subsection (4)(b) a fee in an
297		amount that the department sets in accordance with Section 63J-1-504 for the
298		services that the Bureau of Criminal Identification or another authorized agency
299		provides under this section; and
300		(ii) remit the fee described in Subsection (4)(d)(i) to the Bureau of Criminal

301	Identification.
302	(5)(a) The department shall designate, on an individual's cannabis production establishment
303	agent registration card
304	the type of cannabis production establishment for which the individual is authorized to
305	act as an agent.
306	(b) When issuing a card under Subsection (5)(a) the department:
307	(i) may issue a cannabis production establishment agent registration card that
308	contains both a cannabis processing facility designation and a cannabis cultivator
309	facility designation; and
310	(ii) if the cannabis production establishment agent registration card will contain an
311	independent cannabis testing laboratory designation, may not include any other
312	designations.
313	(6) A cannabis production establishment agent shall comply with:
314	(a) a certification standard that the department develops; or
315	(b) a certification standard that the department has reviewed and approved.
316	(7)(a) The department shall ensure that the certification standard described in Subsection
317	(6) includes training:
318	(i) in Utah medical cannabis law;
319	(ii) for a cannabis cultivation facility agent, in cannabis cultivation best practices;
320	(iii) for a cannabis processing facility agent, in cannabis processing, manufacturing
321	safety procedures for items for human consumption, and sanitation best practices
322	and
323	(iv) for an independent cannabis testing laboratory agent, in cannabis testing best
324	practices.
325	(b) The department shall review the training described in Subsection (7)(a) annually or
326	as often as necessary to ensure compliance with this section.
327	(8) For an individual who holds or applies for a cannabis production establishment agent
328	registration card:
329	(a) the department may revoke or refuse to issue the card if the individual violates the
330	requirements of this chapter; and
331	(b) the department shall revoke or refuse to issue the card if the individual is convicted
332	under state or federal law of:
333	(i) a felony in the preceding 10 years; or
334	(ii) after December 3, 2018, a misdemeanor for drug distribution.

335	(9)(a) A cannabis production establishment agent registration card expires two years
336	after the day on which the department issues the card.
337	(b) A cannabis production establishment agent may renew the agent's registration card if
338	the agent:
339	(i) is eligible for a cannabis production establishment registration card under this
340	section;
341	(ii) certifies to the department in a renewal application that the information in
342	Subsection (4)(a) is accurate or updates the information; and
343	(iii) pays to the department a renewal fee in an amount that:
344	(A) subject to Subsection 4-41a-104(5), the department sets in accordance with
345	Section 63J-1-504; and
346	(B) may not exceed the cost of the relatively lower administrative burden of
347	renewal in comparison to the original application process.
348	(10) A cannabis production establishment shall:
349	(a) maintain a list of each employee that holds a cannabis production establishment
350	agent registration card; and
351	(b) provide the list to the department upon request.
352	Section 3. Section <b>4-41a-602</b> is amended to read:
353	4-41a-602. Cannabis product Labeling and child-resistant packaging.
354	(1) For any cannabis product that a cannabis processing facility processes or produces and
355	for any raw cannabis that the facility packages, the facility shall:
356	(a) label the cannabis or cannabis product with a label that:
357	(i) clearly and unambiguously states that the cannabis product or package contains
358	cannabis;
359	(ii) clearly displays the amount of total composite tetrahydrocannabinol, cannabidiol,
360	and any known cannabinoid that is greater than 1% of the total cannabinoids
361	contained in the cannabis or cannabis product as determined under Subsection
362	4-41a-701(4);
363	(iii) has a unique identification number that:
364	(A) is connected to the inventory control system; and
365	(B) identifies the unique cannabis product manufacturing process the cannabis
366	processing facility used to manufacture the cannabis product;
367	(iv) identifies the cannabinoid extraction process that the cannabis processing facility
368	used to create the cannabis product;

369	(v) does not display an image, word, or phrase that the facility knows or should know
370	appeals to children; and
371	(vi) discloses each active or potentially active ingredient, in order of prominence, and
372	possible allergen; and
373	(b) package the raw cannabis or cannabis product in a medicinal dosage form in a
374	container that:
375	(i) is tamper evident and tamper resistant;
376	(ii) does not appeal to children;
377	(iii) does not mimic a candy container;
378	(iv) complies with child-resistant effectiveness standards that the United States
379	Consumer Product Safety Commission establishes;
380	(v) includes a warning label that states:
381	[(A) for a container labeled before July 1, 2021, "WARNING: Cannabis has
382	intoxicating effects and may be addictive. Do not operate a vehicle or
383	machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This
384	product is for medical use only. Use only as directed by a qualified medical
385	provider.";]
386	[(B)] (A) for a container labeled on or after July 1, 2021, "WARNING: Cannabis
387	has intoxicating effects and may be addictive. Do not operate a vehicle or
388	machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This
389	product is for medical use only. Use only as directed by a recommending
390	medical provider."; or
391	[(C)] (B) for a container labeled on or after January 1, 2024, "WARNING:
392	Cannabis has intoxicating effects, may be addictive, and may increase risk of
393	mental illness. Do not operate a vehicle or machinery under its influence.
394	KEEP OUT OF REACH OF CHILDREN. This product is for medical use
395	only. Use only as directed by a recommending medical provider."; and
396	(vi) for raw cannabis or a cannabis product sold in a vaporizer cartridge labeled on or
397	after May 3, 2023, includes a warning label that states:
398	(A) "WARNING: Vaping of cannabis-derived products has been associated with
399	lung injury."; and
400	(B) "WARNING: Inhalation of cannabis smoke has been associated with lung
401	injury.".
402	(2) To ensure that a cannabis product that a cannabis processing facility processes or

403	produces has a medical rather than recreational disposition, the facility may not produce
404	or process a product whose logo, product name, or brand name includes terms related to
405	recreational marijuana, including "weed," "pot," "reefer," "grass," "hash," "ganja,"
406	"Mary Jane," "high," "haze," "stoned," "joint," "bud," "smoke," "euphoria," "dank,"
407	"doobie," "kush," "frost," "cookies," "rec," "bake," "blunt," "combust," "bong,"
408	"budtender," "dab," "blaze," "toke," or "420."
409	(3) For any cannabis or cannabis product that the cannabis processing facility processes into
410	a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or rectangular
411	cuboid shape, the facility shall:
412	(a) ensure that the label described in Subsection (1)(a) does not contain a photograph or
413	other image of the content of the container; and
414	(b) include on the label described in Subsection (1)(a) a warning about the risks of
415	over-consumption.
416	(4) For any cannabis product that contains an artificially derived cannabinoid, the cannabis
417	processing facility shall ensure that the label clearly:
418	(a) identifies each artificially derived cannabinoid; and
419	(b) identifies that each artificially derived cannabinoid is an artificially derived
420	cannabinoid.
421	(5) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the
422	department:
423	(a) shall make rules to establish:
424	(i) a standard labeling format that:
425	(A) complies with the requirements of this section; and
426	(B) ensures inclusion of a pharmacy label; and
427	(ii) additional requirements on packaging for cannabis and cannabis products to
428	ensure safety and product quality; and
429	(b) may make rules to further define standards regarding images, words, phrases, or
430	containers that may appeal to children under Subsection (1)(a)(v) or (1)(b)(ii).
431	Section 4. Section <b>4-41a-1101</b> is amended to read:
432	4-41a-1101 . Operating requirements General.
433	(1)(a) A medical cannabis pharmacy shall operate:
434	(i) at the physical address provided to the department under Section 4-41a-1001; and
435	(ii) in accordance with the operating plan provided to the department under Section
436	4-41a-1001 and, if applicable, Section 4-41a-1004.

- 437 (b) A medical cannabis pharmacy shall notify the department before a change in the 438 medical cannabis pharmacy's physical address or operating plan. 439 (2) An individual may not enter a medical cannabis pharmacy unless the individual: 440 (a) is at least 18 years old or is an emancipated minor under Section 80-7-105; and 441 (b) except as provided in Subsection (4): 442 (i) possesses a valid: 443 (A) medical cannabis pharmacy agent registration card; 444 (B) pharmacy medical provider registration card; or 445 (C) medical cannabis card; 446 (ii) is an employee of the department performing an inspection under Section 447 4-41a-1103; or 448 (iii) is another individual as the department provides. 449 (3) A medical cannabis pharmacy may not employ an individual who is younger than 21 450 years old. (4) Notwithstanding Subsection (2)(a), a medical cannabis pharmacy may authorize an 451 452 individual who is not a medical cannabis pharmacy agent or pharmacy medical provider 453 to access the medical cannabis pharmacy if the medical cannabis pharmacy tracks and 454 monitors the individual at all times while the individual is at the medical cannabis 455 pharmacy and maintains a record of the individual's access. 456 (5) A medical cannabis pharmacy shall operate in a facility that has: 457 (a) a single, secure public entrance; 458 (b) a security system with a backup power source that: 459 (i) detects and records entry into the medical cannabis pharmacy; and 460 (ii) provides notice of an unauthorized entry to law enforcement when the medical 461 cannabis pharmacy is closed; and 462 (c) a lock on each area where the medical cannabis pharmacy stores cannabis or a 463 cannabis product. 464 (6) A medical cannabis pharmacy shall post, both clearly and conspicuously in the medical 465 cannabis pharmacy, the limit on the purchase of cannabis described in Subsection 466 4-41a-1102(2). 467 (7) Except for an emergency situation described in Subsection 26B-4-213(3)(c), a medical 468 cannabis pharmacy may not allow any individual to consume cannabis on the property 469 or premises of the medical cannabis pharmacy.
  - (8) A medical cannabis pharmacy may not sell cannabis or a cannabis product without first

471	indicating on the cannabis or cannabis product label the name of the medical cannabis
472	pharmacy.
473	(9)(a) Each medical cannabis pharmacy shall retain in the pharmacy's records the
474	following information regarding each recommendation underlying a transaction:
475	(i) the recommending medical provider's name, address, and telephone number;
476	(ii) the patient's name and address;
477	(iii) the date of issuance;
478	(iv) directions of use and dosing guidelines or an indication that the recommending
479	medical provider did not recommend specific directions of use or dosing
480	guidelines; and
481	(v) if the patient did not complete the transaction, the name of the medical cannabis
482	cardholder who completed the transaction.
483	(b)(i) Except as provided in Subsection (9)(b)(iii), a medical cannabis pharmacy may
484	not sell medical cannabis unless the medical cannabis has a label securely affixed
485	to the container indicating the following minimum information:
486	(A) the name, address, and telephone number of the medical cannabis pharmacy;
487	(B) the unique identification number that the medical cannabis pharmacy assigns;
488	(C) the date of the sale;
489	(D) the name of the patient;
490	(E) the name of the recommending medical provider who recommended the
491	medical cannabis treatment;
492	(F) directions for use and cautionary statements, if any;
493	(G) the amount dispensed and the cannabinoid content;
494	(H) the suggested use date;
495	(I) for unprocessed cannabis flower, the legal use termination date; and
496	(J) any other requirements that the department determines, in consultation with the
497	Division of Professional Licensing and the Board of Pharmacy.
498	(ii) A medical cannabis pharmacy is exempt from the requirement to provide the
499	following information under Subsection (9)(b)(i) if the information is already
500	provided on the product label that a cannabis production establishment affixes:
501	(A) a unique identification number;
502	(B) directions for use and cautionary statements;
503	(C) amount and cannabinoid content; and
504	(D) a suggested use date.

505		(iii) If the size of a medical cannabis container does not allow sufficient space to
506		include the labeling requirements described in Subsection (9)(b)(i), the medical
507		cannabis pharmacy may provide the following information described in
508		Subsection (9)(b)(i) on a supplemental label attached to the container or an
509		informational enclosure that accompanies the container:
510		(A) the cannabinoid content;
511		(B) the suggested use date; and
512		(C) any other requirements that the department determines.
513		(iv) A medical cannabis pharmacy may sell medical cannabis to another medical
514		cannabis pharmacy without a label described in Subsection (9)(b)(i).
515	(10) A	pharmacy medical provider or medical cannabis pharmacy agent shall:
516	(a)	upon receipt of an order from a [limited medical provider] recommending medical
517		provider in accordance with Subsections 26B-4-204(1)(b) [through (d)] and (c):
518		(i) for a written order or an electronic order under circumstances that the department
519		determines, contact the [limited medical provider] recommending medical provider
520		or the [limited medical provider's] recommending medical provider's office to
521		verify the validity of the recommendation; and
522		(ii) for an order that the pharmacy medical provider or medical cannabis pharmacy
523		agent verifies under Subsection (10)(a)(i) or an electronic order that is not subject
524		to verification under Subsection (10)(a)(i), enter the [limited medical provider's]
525		recommending medical provider's recommendation or renewal, including any
526		associated directions of use, dosing guidelines, or caregiver indication, in the state
527		electronic verification system;
528	(b)	in processing an order for a holder of a conditional medical cannabis card described
529		in Subsection 26B-4-213(1)(b) that appears irregular or suspicious in the judgment of
530		the pharmacy medical provider or medical cannabis pharmacy agent, contact the
531		recommending medical provider or the recommending medical provider's office to
532		verify the validity of the recommendation before processing the cardholder's order;
533	(c)	unless the medical cannabis cardholder has had a consultation under Subsection
534		26B-4-231(5), verbally offer to a medical cannabis cardholder at the time of a
535		purchase of cannabis, a cannabis product, or a medical cannabis device, personal
536		counseling with the pharmacy medical provider; and
537	(d)	provide a telephone number or website by which the cardholder may contact a
538		pharmacy medical provider for counseling.

539	(11)(a) A medical cannabis pharmacy may create a medical cannabis disposal program
540	that allows an individual to deposit unused or excess medical cannabis or cannabis
541	residue from a medical cannabis device in a locked box or other secure receptacle
542	within the medical cannabis pharmacy.
543	(b) A medical cannabis pharmacy with a disposal program described in Subsection
544	(11)(a) shall ensure that only a medical cannabis pharmacy agent or pharmacy
545	medical provider can access deposited medical cannabis.
546	(c) A medical cannabis pharmacy shall dispose of any deposited medical cannabis by:
547	(i) rendering the deposited medical cannabis unusable and unrecognizable before
548	transporting deposited medical cannabis from the medical cannabis pharmacy; and
549	(ii) disposing of the deposited medical cannabis in accordance with:
550	(A) federal and state law, rules, and regulations related to hazardous waste;
551	(B) the Resource Conservation and Recovery Act, 42 U.S.C. Sec. 6991 et seq.;
552	(C) Title 19, Chapter 6, Part 5, Solid Waste Management Act; and
553	(D) other regulations that the department makes in accordance with Title 63G,
554	Chapter 3, Utah Administrative Rulemaking Act.
555	(12) A medical cannabis pharmacy:
556	(a) shall employ a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy
557	Practice Act, as a pharmacy medical provider;
558	(b) may employ a physician who has the authority to write a prescription and is licensed
559	under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah
560	Osteopathic Medical Practice Act, as a pharmacy medical provider;
561	(c) shall ensure that a pharmacy medical provider described in Subsection (12)(a) works
562	onsite during all business hours;
563	(d) shall designate one pharmacy medical provider described in Subsection (12)(a) as the
564	pharmacist-in-charge to oversee the operation of and generally supervise the medical
565	cannabis pharmacy; and
566	(e) shall allow the pharmacist-in-charge to determine which cannabis and cannabis
567	products the medical cannabis pharmacy maintains in the medical cannabis
568	pharmacy's inventory.
569	(13) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah
570	Administrative Rulemaking Act, protocols for a recall of cannabis and cannabis products
571	by a medical cannabis pharmacy.
572	Section 5. Section <b>26B-1-435</b> is amended to read:

573	26B-1-435 . Medical Cannabis Policy Advisory Board creation Membership
574	Duties.
575	(1) There is created within the department the Medical Cannabis Policy Advisory Board.
576	(2)(a) The advisory board shall consist of the following members:
577	(i) appointed by the executive director:
578	(A) a [qualified medical provider] recommending medical provider who has
579	recommended medical cannabis to at least 100 patients before being appointed;
580	(B) a medical research professional;
581	(C) a mental health specialist;
582	(D) an individual who represents an organization that advocates for medical
583	cannabis patients;
584	(E) an individual who holds a medical cannabis patient card; and
585	(F) a member of the general public who does not hold a medical cannabis card; and
586	(ii) appointed by the commissioner of the Department of Agriculture and Food:
587	(A) an individual who owns or operates a licensed cannabis cultivation facility, as
588	defined in Section 4-41a-102;
589	(B) an individual who owns or operates a licensed medical cannabis pharmacy;
590	and
591	(C) a law enforcement officer.
592	(b) The commissioner of the Department of Agriculture and Food shall ensure that at
593	least one individual appointed under Subsection (2)(a)(ii)(A) or (B) also owns or
594	operates a licensed cannabis processing facility.
595	(3)(a) Subject to Subsection (3)(b), a member of the advisory board shall serve for a four
596	year term.
597	(b) When appointing the initial membership of the advisory board, the executive director
598	and the commissioner of the Department of Agriculture and Food shall coordinate to
599	appoint four advisory board members to serve a term of two years to ensure that
600	approximately half of the board is appointed every two years.
601	(4)(a) If an advisory board member is no longer able to serve as a member, a new
602	member shall be appointed in the same manner as the original appointment.
603	(b) A member appointed in accordance with Subsection (4)(a) shall serve for the
604	remainder of the unexpired term of the original appointment.
605	(5)(a) A majority of the advisory board members constitutes a quorum.
606	(b) The action of a majority of a quorum constitutes an action of the advisory board.

607		(c) For a term lasting one year, the advisory board shall annually designate members of
608		the advisory board to serve as chair and vice-chair.
609		(d) When designating the chair and vice-chair, the advisory board shall ensure that at
610		least one individual described Subsection (2)(a)(i) is appointed as chair or vice-chair.
611	(6)	An advisory board member may not receive compensation or benefits for the member's
612		service on the advisory board but may receive per diem and reimbursement for travel
613		expenses incurred as an advisory board member in accordance with:
614		(a) Sections 63A-3-106 and 63A-3-107; and
615		(b) rules made by the Division of Finance pursuant to Sections 63A-3-106 and
616		63A-3-107.
617	(7)	The department shall:
618		(a) provide staff support for the advisory board; and
619		(b) assist the advisory board in conducting meetings.
620	(8)	The advisory board may recommend:
621		(a) to the department or the Department of Agriculture and Food changes to current or
622		proposed medical cannabis rules or statutes; and
623		(b) to the appropriate legislative committee whether the advisory board supports a
624		change to medical cannabis statutes.
625	(9)	The advisory board shall:
626		(a) review any draft rule that is authorized under this chapter or Title 4, Chapter 41a,
627		Cannabis Production Establishments and Pharmacies;
628		(b) consult with the Department of Agriculture and Food regarding the issuance of an
629		additional:
630		(i) cultivation facility license under Section 4-41a-205; or
631		(ii) pharmacy license under Section 4-41a-1005;
632		(c) consult with the department regarding cannabis patient education;
633		(d) consult regarding the reasonableness of any fees set by the department or the
634		Department of Agriculture and Food that pertain to the medical cannabis program;
635		and
636		(e) consult regarding any issue pertaining to medical cannabis when asked by the
637		department or the Utah Department of Agriculture and Food.
638		Section 6. Section <b>26B-2-203</b> is amended to read:
639		26B-2-203 . Services required General acute hospitals Specialty hospitals.
640	(1)	General acute hospitals and specialty hospitals shall remain open and be continuously

- ready to receive patients 24 hours of every day in a year and have an attending medical
- staff consisting of one or more physicians licensed to practice medicine and surgery
- under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah
- Osteopathic Medical Practice Act.
- 645 (2) A specialty hospital shall provide on-site all basic services required of a general acute
- hospital that are needed for the diagnosis, therapy, or rehabilitation offered to or
- required by patients admitted to or cared for in the facility.
- 648 (3)(a) A home health agency shall provide at least licensed nursing services or
- therapeutic services directly through the agency employees.
- (b) A home health agency may provide additional services itself or under arrangements
- with another agency, organization, facility, or individual.
- 652 (4) Beginning January 1, 2023, a hospice program shall provide at least one [qualified
- 653 <u>medical provider</u>] <u>recommending medical provider</u>, as that term is defined in Section
- 654 26B-4-201, for the treatment of hospice patients.
- Section 7. Section **26B-4-201** is amended to read:
- 656 **26B-4-201** . **Definitions**.
- As used in this part:
- 658 (1) "Active tetrahydrocannabinol" means THC, any THC analog, and
- 659 tetrahydrocannabinolic acid.
- 660 (2) "Administration of criminal justice" means the performance of detection, apprehension,
- detention, pretrial release, post-trial release, prosecution, and adjudication.
- 662 (3) "Advertise" means information provided by a person in any medium:
- 663 (a) to the public; and
- (b) that is not age restricted to an individual who is at least 21 years old.
- 665 (4) "Advisory board" means the Medical Cannabis Policy Advisory Board created in
- 666 Section 26B-1-435.
- 667 (5) "Cannabis Research Review Board" means the Cannabis Research Review Board
- created in Section 26B-1-420.
- 669 (6) "Cannabis" means marijuana.
- 670 (7) "Cannabis processing facility" means the same as that term is defined in Section
- 671 4-41a-102.
- (8) "Cannabis product" means a product that:
- 673 (a) is intended for human use; and
- (b) contains cannabis or any tetrahydrocannabinol or THC analog in a total

- concentration of 0.3% or greater on a dry weight basis.
- 676 (9) "Cannabis production establishment" means the same as that term is defined in Section
- 677 4-41a-102.
- 678 (10) "Cannabis production establishment agent" means the same as that term is defined in
- 679 Section 4-41a-102.
- 680 (11) "Cannabis production establishment agent registration card" means the same as that
- term is defined in Section 4-41a-102.
- 682 (12) "Conditional medical cannabis card" means an electronic medical cannabis card that
- the department issues in accordance with Subsection 26B-4-213(1)(b) to allow an
- applicant for a medical cannabis card to access medical cannabis during the department's
- review of the application.
- 686 (13) "Controlled substance database" means the controlled substance database created in
- 687 Section 58-37f-201.
- 688 (14) "Delivery address" means the same as that term is defined in Section 4-41a-102.
- 689 (15) "Department" means the Department of Health and Human Services.
- 690 (16) "Designated caregiver" means:
- 691 (a) an individual:
- (i) whom an individual with a medical cannabis patient card or a medical cannabis
- guardian card designates as the patient's caregiver; and
- (ii) who registers with the department under Section 26B-4-214; or
- (b)(i) a facility that an individual designates as a designated caregiver in accordance
- 696 with Subsection 26B-4-214(1)(b); or
- (ii) an assigned employee of the facility described in Subsection 26B-4-214(1)(b)(ii).
- 698 (17) "Directions of use" means recommended routes of administration for a medical
- cannabis treatment and suggested usage guidelines.
- 700 (18) "Dosing guidelines" means a quantity range and frequency of administration for a
- recommended treatment of medical cannabis.
- 702 (19) "Government issued photo identification" means any of the following forms of
- 703 identification:
- 704 (a) a valid state-issued driver license or identification card;
- (b) a valid United States federal-issued photo identification, including:
- 706 (i) a United States passport;
- 707 (ii) a United States passport card;
- 708 (iii) a United States military identification card; or

742

709	(iv) a permanent resident card or alien registration receipt card; or
710	(c) a foreign passport.
711	(20) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy that
712	the department authorizes, as part of the pharmacy's license, to deliver medical cannabis
713	shipments to a delivery address to fulfill electronic orders that the state central patient
714	portal facilitates.
715	(21) "Inventory control system" means the system described in Section 4-41a-103.
716	(22) "Legal dosage limit" means an amount that:
717	(a) is sufficient to provide 30 days of treatment based on the dosing guidelines that the
718	relevant recommending medical provider or the state central patient portal or
719	pharmacy medical provider, in accordance with Subsection 26B-4-230(5),
720	recommends; and
721	(b) may not exceed:
722	(i) for unprocessed cannabis in a medicinal dosage form, 113 grams by weight; and
723	(ii) for a cannabis product in a medicinal dosage form, a quantity that contains, in
724	total, greater than 20 grams of active tetrahydrocannabinol.
725	(23) "Legal use termination date" means a date on the label of a container of unprocessed
726	cannabis flower:
727	(a) that is 60 days after the date of purchase of the cannabis; and
728	(b) after which, the cannabis is no longer in a medicinal dosage form outside of the
729	primary residence of the relevant medical cannabis patient cardholder.
730	[(24) "Limited medical provider" means an individual who:]
731	[(a) meets the recommending qualifications; and]
732	[(b) has no more than 15 patients with a valid medical cannabis patient card as a result
733	of the individual's recommendation, in accordance with Subsection 26B-4-204(1)(b).]
734	[(25)] (24) "Marijuana" means the same as that term is defined in Section 58-37-2.
735	[(26)] (25) "Medical cannabis" means cannabis in a medicinal dosage form or a cannabis
736	product in a medicinal dosage form.
737	[(27)] (26) "Medical cannabis card" means a medical cannabis patient card, a medical
738	cannabis guardian card, a medical cannabis caregiver card, or a conditional medical
739	cannabis card.
740	[ <del>(28)</del> ] (27) "Medical cannabis cardholder" means:
741	(a) a holder of a medical cannabis card; or

(b) a facility or assigned employee, described in Subsection (16)(b), only:

/43	(1) within the scope of the facility's or assigned employee's performance of the role of
744	a medical cannabis patient cardholder's caregiver designation under Subsection
745	26B-4-214(1)(b); and
746	(ii) while in possession of documentation that establishes:
747	(A) a caregiver designation described in Subsection 26B-4-214(1)(b);
748	(B) the identity of the individual presenting the documentation; and
749	(C) the relation of the individual presenting the documentation to the caregiver
750	designation.
751	[(29)] (28) "Medical cannabis caregiver card" means an electronic document that a
752	cardholder may print or store on an electronic device or a physical card or document that:
753	(a) the department issues to an individual whom a medical cannabis patient cardholder
754	or a medical cannabis guardian cardholder designates as a designated caregiver; and
755	(b) is connected to the electronic verification system.
756	[(30)] (29) "Medical cannabis courier" means the same as that term is defined in Section
757	4-41a-102.
758	[(31)] (30)(a) "Medical cannabis device" means a device that an individual uses to ingest
759	or inhale cannabis in a medicinal dosage form or a cannabis product in a medicinal
760	dosage form.
761	(b) "Medical cannabis device" does not include a device that:
762	(i) facilitates cannabis combustion; or
763	(ii) an individual uses to ingest substances other than cannabis.
764	[(32)] (31) "Medical cannabis guardian card" means an electronic document that a
765	cardholder may print or store on an electronic device or a physical card or document that:
766	(a) the department issues to the parent or legal guardian of a minor with a qualifying
767	condition; and
768	(b) is connected to the electronic verification system.
769	[(33)] (32) "Medical cannabis patient card" means an electronic document that a cardholder
770	may print or store on an electronic device or a physical card or document that:
771	(a) the department issues to an individual with a qualifying condition; and
772	(b) is connected to the electronic verification system.
773	[(34)] (33) "Medical cannabis pharmacy" means a person that:
774	(a)(i) acquires or intends to acquire medical cannabis or a cannabis product in a
775	medicinal dosage form from a cannabis processing facility or another medical
776	cannahis pharmacy or a medical cannahis device: or

///	(11) possesses medical cannabis or a medical cannabis device; and	
778	(b) sells or intends to sell medical cannabis or a medical cannabis device to a medical	
779	cannabis cardholder.	
780	[(35)] (34) "Medical cannabis pharmacy agent" means an individual who holds a valid	
781	medical cannabis pharmacy agent registration card issued by the department.	
782	[(36)] (35) "Medical cannabis pharmacy agent registration card" means a registration card	
783	issued by the department that authorizes an individual to act as a medical cannabis	
784	pharmacy agent.	
785	[(37)] (36) "Medical cannabis shipment" means the same as that term is defined in Section	
786	4-41a-102.	
787	[(38)] (37) "Medical cannabis treatment" means cannabis in a medicinal dosage form, a	
788	cannabis product in a medicinal dosage form, or a medical cannabis device.	
789	[ <del>(39)</del> ] (38)(a) "Medicinal dosage form" means:	
790	(i) for processed medical cannabis, the following with a specific and consistent	
791	cannabinoid content:	
792	(A) a tablet;	
793	(B) a capsule;	
794	(C) a concentrated liquid or viscous oil;	
795	(D) a liquid suspension that does not exceed 30 milliliters;	
796	(E) a topical preparation;	
797	(F) a transdermal preparation;	
798	(G) a sublingual preparation;	
799	(H) a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or	
800	rectangular cuboid shape;	
801	(I) a resin or wax;	
802	(J) an aerosol;	
803	(K) a suppository preparation; or	
804	(L) a soft or hard confection that is a uniform rectangular cuboid or uniform	
805	spherical shape, is homogeneous in color and texture, and each piece is a sir	ıgle
806	serving; or	
807	(ii) for unprocessed cannabis flower, a container described in Section 4-41a-602 that	ıt:
808	(A) contains cannabis flower in a quantity that varies by no more than 10% from	n
809	the stated weight at the time of packaging;	
810	(B) at any time the medical cannabis cardholder transports or possesses the	

811	container in public, is contained within an opaque bag or box that the medical
812	cannabis pharmacy provides; and
813	(C) is labeled with the container's content and weight, the date of purchase, the
814	legal use termination date, and a barcode that provides information connected
815	to an inventory control system.
816	(b) "Medicinal dosage form" includes a portion of unprocessed cannabis flower that:
817	(i) the medical cannabis cardholder has recently removed from the container
818	described in Subsection [(39)(a)(ii)] (38)(a)(ii) for use; and
819	(ii) does not exceed the quantity described in Subsection [(39)(a)(ii)] (38)(a)(ii).
820	(c) "Medicinal dosage form" does not include:
821	(i) any unprocessed cannabis flower outside of the container described in Subsection [
822	(39)(a)(ii)] $(38)(a)(ii)$ , except as provided in Subsection $[(39)(b)]$ $(38)(b)$ ;
823	(ii) any unprocessed cannabis flower in a container described in Subsection [
824	(39)(a)(ii)] (38)(a)(ii) after the legal use termination date;
825	(iii) a process of vaporizing and inhaling concentrated cannabis by placing the
826	cannabis on a nail or other metal object that is heated by a flame, including a
827	blowtorch;
828	(iv) a liquid suspension that is branded as a beverage;
829	(v) a substance described in Subsection $[(39)(a)(i)]$ $(38)(a)(i)$ or (ii) if the substance is
830	not measured in grams, milligrams, or milliliters; or
831	(vi) a substance that contains or is covered to any degree with chocolate.
832	[(40)] (39) "Nonresident patient" means an individual who:
833	(a) is not a resident of Utah or has been a resident of Utah for less than 45 days;
834	(b) has a currently valid medical cannabis card or the equivalent of a medical cannabis
835	card under the laws of another state, district, territory, commonwealth, or insular
836	possession of the United States; and
837	(c) has been diagnosed with a qualifying condition as described in Section 26B-4-203.
838	[(41)] (40) "Pharmacy medical provider" means the medical provider required to be on site
839	at a medical cannabis pharmacy under Section 26B-4-219.
840	[(42)] (41) "Provisional patient card" means a card that:
841	(a) the department issues to a minor with a qualifying condition for whom:
842	(i) a recommending medical provider has recommended a medical cannabis
843	treatment; and
844	(ii) the department issues a medical cannabis quardian card to the minor's parent or

845	legal guardian; and
846	(b) is connected to the electronic verification system.
847	[(43) "Qualified medical provider" means an individual:]
848	[(a) who meets the recommending qualifications; and]
849	[(b) whom the department registers to recommend treatment with cannabis in a
850	medicinal dosage form under Section 26B-4-204.]
851	[(44)] (42) "Qualified Patient Enterprise Fund" means the enterprise fund created in Section
852	26B-1-310.
853	[(45)] (43) "Qualifying condition" means a condition described in Section 26B-4-203.
854	[(46)] (44) "Recommend" or "recommendation" means, for a recommending medical
855	provider, the act of suggesting the use of medical cannabis treatment, which:
856	(a) certifies the patient's eligibility for a medical cannabis card; and
857	(b) may include, at the recommending medical provider's discretion, directions of use,
858	with or without dosing guidelines.
859	[(47)] (45) "Recommending medical provider" [means a qualified medical provider or a
860	limited medical provider] means an individual who meets the recommending
861	qualifications.
862	[(48)] (46) "Recommending qualifications" means that an individual:
863	(a)(i) has the authority to write a prescription;
864	(ii) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah
865	Controlled Substances Act; and
866	(iii) possesses the authority, in accordance with the individual's scope of practice, to
867	prescribe a Schedule II controlled substance; and
868	(b) is licensed as:
869	(i) a podiatrist under Title 58, Chapter 5a, Podiatric Physician Licensing Act;
870	(ii) an advanced practice registered nurse under Title 58, Chapter 31b, Nurse Practice
871	Act;
872	(iii) a physician under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58,
873	Chapter 68, Utah Osteopathic Medical Practice Act; or
874	(iv) a physician assistant under Title 58, Chapter 70a, Utah Physician Assistant Act.
875	[(49)] (47) "State central patient portal" means the website the department creates, in
876	accordance with Section 26B-4-236, to facilitate patient safety, education, and an
877	electronic medical cannabis order.
878	[(50)] (48) "State electronic verification system" means the system described in Section

879	26B-4-202.
880	[(51)] (49) "Targeted marketing" means the promotion by a [qualified medical provider]
881	recommending medical provider, medical clinic, or medical office that employs a [
882	qualified medical provider] recommending medical provider of a medical cannabis
883	recommendation service using any of the following methods:
884	(a) electronic communication to an individual who is at least 21 years old and has
885	requested to receive promotional information;
886	(b) an in-person marketing event that is held in an area where only an individual who is
887	at least 21 years old may access the event;
888	(c) other marketing material that is physically or digitally displayed in the office of the
889	medical clinic or office that employs a [qualified medical provider] recommending
890	medical provider; or
891	(d) a leaflet that a [qualified medical provider] recommending medical provider, medical
892	clinic, or medical office that employs a [qualified medical provider] recommending
893	medical provider shares with an individual who is at least 21 years old.
894	[(52)] (50) "Tetrahydrocannabinol" or "THC" means a substance derived from cannabis or a
895	synthetic equivalent as described in Subsection 58-37-4(2)(a)(iii)(AA).
896	[(53)] (51) "THC analog" means the same as that term is defined in Section 4-41-102.
897	Section 8. Section <b>26B-4-202</b> is amended to read:
898	26B-4-202 . Electronic verification system.
899	(1) The Department of Agriculture and Food, the department, the Department of Public
900	Safety, and the Division of Technology Services shall:
901	(a) enter into a memorandum of understanding in order to determine the function and
902	operation of the state electronic verification system in accordance with Subsection
903	(2);
904	(b) coordinate with the Division of Purchasing, under Title 63G, Chapter 6a, Utah
905	Procurement Code, to develop a request for proposals for a third-party provider to
906	develop and maintain the state electronic verification system in coordination with the
907	Division of Technology Services; and
908	(c) select a third-party provider who:
909	(i) meets the requirements contained in the request for proposals issued under
910	Subsection (1)(b); and
911	(ii) may not have any commercial or ownership interest in a cannabis production
912	establishment or a medical cannabis pharmacy.

913	(2) The Department of Agriculture and Food, the department, the Department of Public
914	Safety, and the Division of Technology Services shall ensure that the state electronic
915	verification system described in Subsection (1):
916	(a) allows an individual to apply for a medical cannabis patient card or, if applicable, a
917	medical cannabis guardian card, provided that the card may not become active until:
918	(i) the relevant [qualified medical provider] recommending medical provider
919	completes the associated medical cannabis recommendation; or
920	(ii) [for a medical cannabis card related to a limited medical provider's
921	recommendation, ]the medical cannabis pharmacy completes the recording
922	described in Subsection (2)(d);
923	(b) allows an individual to apply to renew a medical cannabis patient card or a medical
924	cannabis guardian card in accordance with Section 26B-4-213;
925	(c) allows a [qualified medical provider] recommending medical provider, or an
926	employee described in Subsection (3) acting on behalf of the [qualified medical
927	provider] recommending medical provider, to:
928	(i) access dispensing and card status information regarding a patient:
929	(A) with whom the [qualified medical provider] recommending medical provider
930	has a provider-patient relationship; and
931	(B) for whom the [qualified medical provider] recommending medical provider
932	has recommended or is considering recommending a medical cannabis card;
933	(ii) electronically recommend treatment with cannabis in a medicinal dosage form or
934	a cannabis product in a medicinal dosage form and optionally recommend dosing
935	guidelines;
936	(iii) electronically renew a recommendation to a medical cannabis patient cardholder
937	or medical cannabis guardian cardholder:
938	(A) using telehealth services, for the [qualified medical provider] recommending
939	medical provider who originally recommended a medical cannabis treatment
940	during a face-to-face visit with the patient; or
941	(B) during a face-to-face visit with the patient, for a [qualified medical provider]
942	recommending medical provider who did not originally recommend the
943	medical cannabis treatment during a face-to-face visit; and
944	(iv) submit an initial application, renewal application, or application payment on
945	behalf of an individual applying for any of the following:
946	(A) a medical cannabis patient card;

947	(B) a medical cannabis guardian card; or
948	(C) a medical cannabis caregiver card;
949	(d) allows a medical cannabis pharmacy medical provider or medical cannabis pharmacy
950	agent, in accordance with Subsection 4-41a-1101(10)(a), to:
951	(i) access the electronic verification system to review the history within the system of
952	a patient with whom the provider or agent is interacting, limited to read-only
953	access for medical cannabis pharmacy agents unless the medical cannabis
954	pharmacy's pharmacist in charge authorizes add and edit access;
955	(ii) record a patient's recommendation from a [limited medical provider]
956	recommending medical provider, including any directions of use, dosing
957	guidelines, or caregiver indications from the [limited medical provider]
958	recommending medical provider;
959	(iii) record a [limited medical provider's] recommending medical provider's renewal
960	of the provider's previous recommendation; and
961	(iv) submit an initial application, renewal application, or application payment on
962	behalf of an individual applying for any of the following:
963	(A) a medical cannabis patient card;
964	(B) a medical cannabis guardian card; or
965	(C) a medical cannabis caregiver card;
966	(e) connects with:
967	(i) an inventory control system that a medical cannabis pharmacy uses to track in real
968	time and archive purchases of any cannabis in a medicinal dosage form, cannabis
969	product in a medicinal dosage form, or a medical cannabis device, including:
970	(A) the time and date of each purchase;
971	(B) the quantity and type of cannabis, cannabis product, or medical cannabis
972	device purchased;
973	(C) any cannabis production establishment, any medical cannabis pharmacy, or
974	any medical cannabis courier associated with the cannabis, cannabis product,
975	or medical cannabis device; and
976	(D) the personally identifiable information of the medical cannabis cardholder
977	who made the purchase; and
978	(ii) any commercially available inventory control system that a cannabis production
979	establishment utilizes in accordance with Section 4-41a-103 to use data that the
980	Department of Agriculture and Food requires by rule, in accordance with Title

981	63G, Chapter 3, Utah Administrative Rulemaking Act, from the inventory
982	tracking system that a licensee uses to track and confirm compliance;
983	(f) provides access to:
984	(i) the department to the extent necessary to carry out the department's functions and
985	responsibilities under this part;
986	(ii) the Department of Agriculture and Food to the extent necessary to carry out the
987	functions and responsibilities of the Department of Agriculture and Food under
988	Title 4, Chapter 41a, Cannabis Production Establishments and Pharmacies; and
989	(iii) the Division of Professional Licensing to the extent necessary to carry out the
990	functions and responsibilities related to the participation of the following in the
991	recommendation and dispensing of medical cannabis:
992	(A) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing
993	Act;
994	(B) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;
995	(C) an advanced practice registered nurse licensed under Title 58, Chapter 31b,
996	Nurse Practice Act;
997	(D) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or
998	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or
999	(E) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician
1000	Assistant Act;
1001	(g) provides access to and interaction with the state central patient portal;
1002	(h) communicates dispensing information from a record that a medical cannabis
1003	pharmacy submits to the state electronic verification system under Subsection
1004	4-41a-1102(3)(a)(ii) to the controlled substance database;
1005	(i) provides access to state or local law enforcement only to verify the validity of an
1006	individual's medical cannabis card for the administration of criminal justice and
1007	through a database used by law enforcement; and
1008	(j) creates a record each time a person accesses the system that identifies the person who
1009	accesses the system and the individual whose records the person accesses.
1010	(3)(a) An employee of a [qualified medical provider] recommending medical provider
1011	may access the electronic verification system for a purpose described in Subsection
1012	(2)(c) on behalf of the [qualified medical provider] recommending medical provider if:
1013	(i) the [qualified medical provider] recommending medical provider has designated
1014	the employee as an individual authorized to access the electronic verification

1015	system on behalf of the [qualified medical provider] recommending medical
1016	provider;
1017	(ii) the [qualified medical provider] recommending medical provider provides written
1018	notice to the department of the employee's identity and the designation described
1019	in Subsection (3)(a)(i); and
1020	(iii) the department grants to the employee access to the electronic verification
1021	system.
1022	(b) An employee of a business that employs a [qualified medical provider]
1023	recommending medical provider may access the electronic verification system for a
1024	purpose described in Subsection (2)(c) on behalf of the [qualified medical provider]
1025	recommending medical provider if:
1026	(i) the [qualified medical provider] recommending medical provider has designated
1027	the employee as an individual authorized to access the electronic verification
1028	system on behalf of the [qualified medical provider] recommending medical
1029	provider;
1030	(ii) the [qualified medical provider] recommending medical provider and the
1031	employing business jointly provide written notice to the department of the
1032	employee's identity and the designation described in Subsection (3)(b)(i); and
1033	(iii) the department grants to the employee access to the electronic verification
1034	system.
1035	(4)(a) As used in this Subsection (4), "prescribing provider" means:
1036	(i) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act;
1037	(ii) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse
1038	Practice Act;
1039	(iii) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or
1040	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or
1041	(iv) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician
1042	Assistant Act.
1043	(b) A prescribing provider may access information in the electronic verification system
1044	regarding a patient the prescribing provider treats.
1045	(5) The department may release limited data that the system collects for the purpose of:
1046	(a) conducting medical and other department approved research;
1047	(b) providing the report required by Section 26B-4-222; and
1048	(c) other official department purposes.

1049	(6) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah
1050	Administrative Rulemaking Act, to establish:
1051	(a) the limitations on access to the data in the state electronic verification system as
1052	described in this section; and
1053	(b) standards and procedures to ensure accurate identification of an individual requesting
1054	information or receiving information in this section.
1055	(7) Any person who negligently or recklessly releases any information in the state
1056	electronic verification system in violation of this section is guilty of a class C
1057	misdemeanor.
1058	(8) Any person who obtains or attempts to obtain information from the state electronic
1059	verification system by misrepresentation or fraud is guilty of a third degree felony.
1060	(9)(a) Except as provided in Subsections (9)(c) and (9)(e), a person may not knowingly
1061	and intentionally use, release, publish, or otherwise make available to any other
1062	person information obtained from the state electronic verification system for any
1063	purpose other than a purpose specified in this section.
1064	(b) Each separate violation of this Subsection (9) is:
1065	(i) a third degree felony; and
1066	(ii) subject to a civil penalty not to exceed \$5,000.
1067	(c) A law enforcement officer who uses the database used by law enforcement to access
1068	information in the electronic verification system for a reason that is not the
1069	administration of criminal justice is guilty of a class B misdemeanor.
1070	(d) The department shall determine a civil violation of this Subsection (9) in accordance
1071	with Title 63G, Chapter 4, Administrative Procedures Act.
1072	(e) Civil penalties assessed under this Subsection (9) shall be deposited into the General
1073	Fund.
1074	(f) This Subsection (9) does not prohibit a person who obtains information from the state
1075	electronic verification system under Subsection (2)(a), (c), or (f) from:
1076	(i) including the information in the person's medical chart or file for access by a
1077	person authorized to review the medical chart or file;
1078	(ii) providing the information to a person in accordance with the requirements of the
1079	Health Insurance Portability and Accountability Act of 1996; or
1080	(iii) discussing or sharing that information about the patient with the patient.
1081	Section 9. Section <b>26B-4-203</b> is amended to read:

26B-4-203 . Qualifying condition.

1083	(1)	By designating a particular condition under Subsection (2) for which the use of medical
1084		cannabis to treat symptoms is decriminalized, the Legislature does not conclusively state
1085		that:
1086		(a) current scientific evidence clearly supports the efficacy of a medical cannabis
1087		treatment for the condition; or
1088		(b) a medical cannabis treatment will treat, cure, or positively affect the condition.
1089	(2)	For the purposes of this part, each of the following conditions is a qualifying condition:
1090		(a) HIV or acquired immune deficiency syndrome;
1091		(b) Alzheimer's disease;
1092		(c) amyotrophic lateral sclerosis;
1093		(d) cancer;
1094		(e) cachexia;
1095		(f) persistent nausea that is not significantly responsive to traditional treatment, except
1096		for nausea related to:
1097		(i) pregnancy;
1098		(ii) cannabis-induced cyclical vomiting syndrome; or
1099		(iii) cannabinoid hyperemesis syndrome;
1100		(g) Crohn's disease or ulcerative colitis;
1101		(h) epilepsy or debilitating seizures;
1102		(i) multiple sclerosis or persistent and debilitating muscle spasms;
1103		(j) post-traumatic stress disorder that is being treated and monitored by a licensed mental
1104		health therapist, as that term is defined in Section 58-60-102, and that:
1105		(i) has been diagnosed by a healthcare provider or mental health provider employed
1106		or contracted by the United States Veterans Administration, evidenced by copies
1107		of medical records from the United States Veterans Administration that are
1108		included as part of the [qualified medical provider's] recommending medical
1109		provider's pre-treatment assessment and medical record documentation; or
1110		(ii) has been diagnosed or confirmed, through face-to-face or telehealth evaluation of
1111		the patient, by a provider who is:
1112		(A) a licensed board-eligible or board-certified psychiatrist;
1113		(B) a licensed psychologist with a master's-level degree;
1114		(C) a licensed clinical social worker with a master's-level degree;
1115		(D) a licensed advanced practice registered nurse who is qualified to practice
1116		within the psychiatric mental health nursing specialty and who has completed

1117	the clinical practice requirements in psychiatric mental health nursing,
1118	including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);
1119	or
1120	(E) a licensed physician assistant who is qualified to specialize in mental health
1121	care under Section 58-70a-501.1;
1122	(k) autism;
1123	(l) a terminal illness when the patient's remaining life expectancy is less than six months;
1124	(m) a condition resulting in the individual receiving hospice care;
1125	(n) a rare condition or disease that:
1126	(i) affects less than 200,000 individuals in the United States, as defined in Section
1127	526 of the Federal Food, Drug, and Cosmetic Act; and
1128	(ii) is not adequately managed despite treatment attempts using:
1129	(A) conventional medications other than opioids or opiates; or
1130	(B) physical interventions;
1131	(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified
1132	medical provider's] recommending medical provider's opinion, despite treatment
1133	attempts using:
1134	(i) conventional medications other than opioids or opiates; or
1135	(ii) physical interventions;
1136	(p) pain that is expected to last for two weeks or longer for an acute condition, including
1137	a surgical procedure, for which a medical professional may generally prescribe
1138	opioids for a limited duration, subject to Subsection 26B-4-213(5)(c); and
1139	(q) a condition that the Compassionate Use Board approves under Section 26B-1-421,
1140	on an individual, case-by-case basis.
1141	Section 10. Section 26B-4-204 is amended to read:
1142	26B-4-204. Treatment recommendation.
1143	(1)(a)(i) [Except as provided in Subsection (1)(b), an individual may not recommend
1144	a medical cannabis treatment unless the department registers the individual as a
1145	qualified medical provider in accordance with this section.] A recommending
1146	medical provider may recommend medical cannabis.
1147	(ii) Notwithstanding Subsection (1)(a)(i), a [qualified medical provider]
1148	recommending medical provider who is podiatrist licensed under Title 58, Chapter
1149	5a, Podiatric Physician Licensing Act, may not recommend a medical cannabis
1150	treatment except within the course and scope of a practice of podiatry, as that term

1151	is defined in Section 58-5a-102.
1152	[(b) An individual who meets the recommending qualifications may recommend a
1153	medical cannabis treatment as a limited medical provider without registering under
1154	Subsection (1)(a) if:]
1155	[(i) the individual recommends the use of medical cannabis to the patient through an
1156	order described in Subsection (1)(e) after:]
1157	[(A) a face-to-face visit for an initial recommendation or the renewal of a
1158	recommendation for a patient for whom the limited medical provider did not
1159	make the patient's original recommendation; or]
1160	[(B) a visit using telehealth services for a renewal of a recommendation for a
1161	patient for whom the limited medical provider made the patient's original
1162	recommendation; and]
1163	[(ii) the individual's recommendation or renewal would not cause the total number of
1164	the individual's patients who have a valid medical cannabis patient card or
1165	provisional patient card resulting from the individual's recommendation to exceed
1166	<del>15.</del> ]
1167	[(e)] (b) [The individual described in Subsection (1)(b) shall ] A recommending medical
1168	provider may communicate the individual's recommendation through an order for the
1169	medical cannabis pharmacy to record the individual's recommendation or renewal in
1170	the state electronic verification system under the individual's recommendation that:
1171	(i)(A) the individual or the individual's employee sends electronically to a medical
1172	cannabis pharmacy; or
1173	(B) the individual gives to the patient in writing for the patient to deliver to a
1174	medical cannabis pharmacy; and
1175	(ii) may include:
1176	(A) directions of use or dosing guidelines; and
1177	(B) an indication of a need for a caregiver in accordance with Subsection
1178	26B-4-213(3)(c).
1179	[(d)] (c) If the [limited medical provider] recommending medical provider gives the
1180	patient a written recommendation to deliver to a medical cannabis pharmacy under
1181	Subsection [(1)(c)(i)(B), the limited medical provider] (1)(b)(i)(B), the recommending
1182	medical provider shall ensure that the document includes all of the information that is
1183	included on a prescription the provider would issue for a controlled substance,
1184	including.

1185	(i) the date of issuance;
1186	(ii) the provider's name, address and contact information, controlled substance license
1187	information, and signature; and
1188	(iii) the patient's name, address and contact information, age, and diagnosed
1189	qualifying condition.
1190	[(e)] (d) In considering making a recommendation as a [limited medical provider]
1191	recommending medical provider, an individual may consult information that the
1192	department makes available on the department's website for recommending providers.
1193	[(3)(a) An individual shall complete the continuing education related to medical
1194	cannabis in the following amounts:]
1195	[(i) for an individual as a condition precedent to registration, four hours; and]
1196	[(ii) for a qualified medical provider as a condition precedent to renewal, four hour
1197	every two years.]
1198	[(2)(a) The department shall, within 15 days after the day on which the department
1199	receives an application from an individual, register and issue a qualified medical
1200	provider registration card to the individual if the individual:
1201	[(i) provides to the department the individual's name and address;]
1202	[(ii) provides to the department an acknowledgment that the individual has completed
1203	four hours of continuing education related to medical cannabis;]
1204	[(iii) provides to the department evidence that the individual meets the
1205	recommending qualifications;]
1206	[(iv) for an applicant on or after November 1, 2021, provides to the department the
1207	information described in Subsection (10)(a); and]
1208	[(v) pays the department a fee in an amount that:]
1209	[(A) the department sets, in accordance with Section 63J-1-504; and]
1210	[(B) does not exceed \$300 for an initial registration.]
1211	[(b) The department may not register an individual as a qualified medical provider if the
1212	individual is:]
1213	[(i) a pharmacy medical provider; or]
1214	[(ii) an owner, officer, director, board member, employee, or agent of a cannabis
1215	production establishment, a medical cannabis pharmacy, or a medical cannabis
1216	eourier.]
1217	[(b)] (2)(a) The department may, in consultation with the Division of Professional
1218	Licensing, develop continuing education related to medical cannabis.

1219	[(e)] (b) The continuing education described in this Subsection [(3)] (2) may discuss:
1220	(i) the provisions of this part;
1221	(ii) general information about medical cannabis under federal and state law;
1222	(iii) the latest scientific research on the endocannabinoid system and medical
1223	cannabis, including risks and benefits;
1224	(iv) recommendations for medical cannabis as it relates to the continuing care of a
1225	patient in pain management, risk management, potential addiction, or palliative
1226	care; and
1227	(v) best practices for recommending the form and dosage of medical cannabis based
1228	on the qualifying condition underlying a medical cannabis recommendation.
1229	[(4)] (3)(a) Except as provided in Subsection [(4)(b)] (3)(b), a [qualified medical provider]
1230	recommending medical provider may not recommend a medical cannabis treatment
1231	to more than 1.5% of the total amount of medical cannabis patient cardholders.
1232	(b) If a [qualified medical provider] recommending medical provider receives payment
1233	from an insurance plan for services provided under this chapter, then the patient
1234	whose insurance plan was billed does not count toward the 1.5% patient cap
1235	described in Subsection $[(4)(a)]$ (3)(a).
1236	[(5)] (4) A recommending medical provider may recommend medical cannabis to an
1237	individual under this part only in the course of a provider-patient relationship after the
1238	recommending medical provider has completed and documented in the patient's medical
1239	record a thorough assessment of the patient's condition and medical history based on the
1240	appropriate standard of care for the patient's condition.
1241	[(6)(a) Except as provided in Subsections (6)(b) and (e), a person may not advertise that
1242	the person or the person's employee recommends a medical cannabis treatment.]
1243	[(b) Notwithstanding Subsection (6)(a) and Section 4-41a-109, a qualified medical
1244	provider, medical clinic, or medical office that employs a qualified medical provider
1245	may advertise only the following:
1246	[(i) a green cross;]
1247	[(ii) the provider's or clinic's name and logo;]
1248	[(iii) a qualifying condition that the individual treats;]
1249	[(iv) that the qualified medical provider, medical clinic, or medical office evaluates
1250	patients for medical cannabis recommendations;]
1251	[(v) a scientific study regarding medical cannabis use; or]
1252	[(vi) contact information.]

1253	(c) Notwithstanding Subsection (6)(a) and Section 4-41a-109, qualified medical
1254	provider, medical clinic, or medical office that employs a qualified medical provider
1255	may engage in targeted marketing, as determined by the department through rule, for
1256	advertising medical cannabis recommendation services.]
1257	[(7)(a) A qualified medical provider registration card expires two years after the day on
1258	which the department issues the card.]
1259	[(b) The department shall renew a qualified medical provider's registration card if the
1260	<del>provider:</del> ]
1261	[(i) applies for renewal;]
1262	[(ii) is eligible for a qualified medical provider registration card under this section,
1263	including maintaining an unrestricted license under the recommending
1264	qualifications;]
1265	[(iii) certifies to the department in a renewal application that the information in
1266	Subsection (2)(a) is accurate or updates the information;]
1267	[(iv) submits a report detailing the completion of the continuing education
1268	requirement described in Subsection (3); and]
1269	[(v) pays the department a fee in an amount that:]
1270	[(A) the department sets, in accordance with Section 63J-1-504; and]
1271	[(B) does not exceed \$50 for a registration renewal.]
1272	[(8) The department may revoke the registration of a qualified medical provider who fails
1273	to maintain compliance with the requirements of this section.]
1274	[(9) A recommending medical provider may not:]
1275	[(a) receive any compensation or benefit for the qualified medical provider's medical
1276	cannabis treatment recommendation from:]
1277	[(i) a cannabis production establishment or an owner, officer, director, board
1278	member, employee, or agent of a cannabis production establishment;]
1279	[(ii) a medical cannabis pharmacy or an owner, officer, director, board member,
1280	employee, or agent of a medical cannabis pharmacy; or]
1281	[(iii) a recommending medical provider or pharmacy medical provider; or]
1282	[(b) provide a medical cannabis recommendation at a medical clinic or medical office
1283	that is violating the advertising limitations described in Subsection (6).]
1284	[(10)] (5)(a) [Each quarter, a qualified medical provider shall report to the department, in
1285	a manner designated by the department:] The department shall host a recommending
1286	provider contact list on the department's website that contains the information

1287	described in Subsection (5)(b).
1288	[(i) if applicable, that the qualified medical provider or the entity that employs the
1289	qualified medical provider represents online or on printed material that the
1290	qualified medical provider is a qualified medical provider or offers medical
1291	eannabis recommendations to patients; and]
1292	[(ii)(A) for eash payment without insurance, the fee amount that the qualified
1293	medical provider or the entity that employs the qualified medical provider
1294	charges a patient for a medical cannabis recommendation as an actual cash
1295	rate; and]
1296	[(B) whether the qualified medical provider or the entity that employs the
1297	qualified medical provider bills insurance.]
1298	(b) [The department shall:] A recommending medical provider that elects to be included
1299	on the contact list shall provide the department the following:
1300	[(i) ensure that the following information related to qualified medical providers and
1301	entities described in Subsection (10)(a)(i) is available on the department's website
1302	or on the health care price transparency tool under Subsection (10)(b)(ii):]
1303	[(A)] (i) the name of the [qualified medical provider] recommending medical provider
1304	and, if applicable, the name of the entity that employs the [qualified medical
1305	provider] recommending medical provider;
1306	[(B)] (ii) the address of the [qualified medical provider's] recommending medical
1307	provider's office or, if applicable, the entity that employs the [qualified medical
1308	provider] recommending medical provider; and
1309	[(C)] (iii)(A) the fee amount [described in Subsection (10)(a)(ii)(A); and] charged
1310	by the recommending medical provider; or
1311	(B) whether the recommending medical provider or entity that employs the
1312	recommending medical provider bills insurance.
1313	[(ii)] (c) The department shall share data collected under this Subsection [(10)] (5) with
1314	the state auditor for use in the health care price transparency tool[-described in
1315	<del>Section 67-3-11</del> ].
1316	Section 11. Section <b>26B-4-205</b> is amended to read:
1317	26B-4-205 . Standard of care Physicians and pharmacists not liable No
1318	private right of action.
1319	(1) An individual described in Subsection (2) is not subject to the following solely for
1320	violating a federal law or regulation that would otherwise prohibit recommending,

1321	prescribing, or dispensing medical cannabis, a medical cannabis product, or a
1322	cannabis-based drug that the United States Food and Drug Administration has not
1323	approved:
1324	(a) civil or criminal liability; or
1325	(b) licensure sanctions under Title 58, Chapter 17b, Pharmacy Practice Act, Title 58,
1326	Chapter 31b, Nurse Practice Act, Title 58, Chapter 67, Utah Medical Practice Act,
1327	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act, or Title 58, Chapter
1328	70a, Utah Physician Assistant Act.
1329	(2) The limitations of liability described in Subsection (1) apply to:
1330	[(a) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act,
1331	an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse
1332	Practice Act, a physician licensed under Title 58, Chapter 67, Utah Medical Practice
1333	Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act, or a physician
1334	assistant licensed under Title 58, Chapter 70a, Utah Physician Assistant Act:]
1335	[(i)(A) whom the department has registered as a qualified medical provider; or]
1336	[(B) who makes a recommendation as a limited medical provider; and]
1337	[(ii)] (a) a recommending medical provider who recommends treatment with cannabis in
1338	a medicinal dosage form or a cannabis product in a medicinal dosage form to a
1339	patient in accordance with this part; and
1340	(b) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act:
1341	(i) whom the department has registered as a pharmacy medical provider; and
1342	(ii) who dispenses, in a medical cannabis pharmacy, treatment with cannabis in a
1343	medicinal dosage form or a cannabis product in a medicinal dosage form to a
1344	medical cannabis cardholder in accordance with this part.
1345	(3) Nothing in this section or part reduces or in any way negates the duty of an individual
1346	described in Subsection (2) to use reasonable and ordinary care in the treatment of a
1347	patient:
1348	(a) who may have a qualifying condition; and
1349	(b)(i) for whom the individual described in Subsection $[(2)(a)(i) \text{ or } (ii)]$ (2)(a) has
1350	recommended or might consider recommending a treatment with cannabis or a
1351	cannabis product; or
1352	(ii) with whom the pharmacist described in Subsection (2)(b) has interacted in the
1353	dosing or dispensing of cannabis or a cannabis product.
1354	(4)(a) As used in this Subsection (4), "healthcare facility" means a health care facility as

1355	defined in Section 26B-2-201.
1356	(b) A healthcare facility may adopt restrictions on the possession, use, and storage of
1357	medical cannabis on the premises of the healthcare facility by a medical cannabis
1358	cardholder who resides at or is actively receiving treatment or care at the healthcare
1359	facility.
1360	(c) An employee or agent of a healthcare facility described in this Subsection (4) is not
1361	subject to civil or criminal liability for carrying out employment duties, including:
1362	(i) providing or supervising care to a medical cannabis cardholder; or
1363	(ii) in accordance with a caregiver designation under Section 26B-4-214 for a
1364	medical cannabis cardholder residing at the healthcare facility, purchasing,
1365	transporting, or possessing medical cannabis for the relevant patient and in
1366	accordance with the designation.
1367	(d) Nothing in this section requires a healthcare facility to adopt a restriction under
1368	Subsection (4)(b).
1369	Section 12. Section <b>26B-4-213</b> is amended to read:
1370	26B-4-213. Medical cannabis patient card Medical cannabis guardian card
1371	Conditional medical cannabis card Application Fees Studies.
1372	(1)(a) Subject to Section 26B-4-246, within 15 days after the day on which an individual
1373	who satisfies the eligibility criteria in this section or Section 26B-4-214 submits an
1374	application in accordance with this section or Section 26B-4-214, the department
1375	shall:
1376	(i) issue a medical cannabis patient card to an individual described in Subsection
1377	(2)(a);
1378	(ii) issue a medical cannabis guardian card to an individual described in Subsection
1379	(2)(b);
1380	(iii) issue a provisional patient card to a minor described in Subsection (2)(c); and
1381	(iv) issue a medical cannabis caregiver card to an individual described in Subsection
1382	26B-4-214(4).
1383	(b)(i) Upon the entry of a recommending medical provider's medical cannabis
1384	recommendation for a patient in the state electronic verification system, either by
1385	the provider or the provider's employee or by a medical cannabis pharmacy
1386	medical provider or medical cannabis pharmacy in accordance with Subsection
1387	4-41a-1101(10)(a), the department shall issue to the patient an electronic
1388	conditional medical cannabis card, in accordance with this Subsection (1)(b).

1389	(ii) A conditional medical cannabis card is valid for the lesser of:
1390	(A) 60 days; or
1391	(B) the day on which the department completes the department's review and issues
1392	a medical cannabis card under Subsection (1)(a), denies the patient's medical
1393	cannabis card application, or revokes the conditional medical cannabis card
1394	under Subsection (8).
1395	(iii) The department may issue a conditional medical cannabis card to an individual
1396	applying for a medical cannabis patient card for which approval of the
1397	Compassionate Use Board is not required.
1398	(iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and
1399	obligations under law applicable to a holder of the medical cannabis card for
1400	which the individual applies and for which the department issues the conditional
1401	medical cannabis card.
1402	(2)(a) An individual is eligible for a medical cannabis patient card if:
1403	(i)(A) the individual is at least 21 years old; or
1404	(B) the individual is 18, 19, or 20 years old, the individual petitions the
1405	Compassionate Use Board under Section 26B-1-421, and the Compassionate
1406	Use Board recommends department approval of the petition;
1407	(ii) the individual is a Utah resident;
1408	(iii) the individual's recommending medical provider recommends treatment with
1409	medical cannabis in accordance with Subsection (4);
1410	(iv) the individual signs an acknowledgment stating that the individual received the
1411	information described in Subsection (9); and
1412	(v) the individual pays to the department a fee in an amount that, subject to
1413	Subsection 26B-1-310(5), the department sets in accordance with Section
1414	63J-1-504.
1415	(b)(i) An individual is eligible for a medical cannabis guardian card if the individual:
1416	(A) is at least 18 years old;
1417	(B) is a Utah resident;
1418	(C) is the parent or legal guardian of a minor for whom the minor's recommending
1419	medical provider recommends a medical cannabis treatment, the individual
1420	petitions the Compassionate Use Board under Section 26B-1-421, and the
1421	Compassionate Use Board recommends department approval of the petition;
1422	(D) the individual signs an acknowledgment stating that the individual received

1423	the information described in Subsection (9); and
1424	(E) pays to the department a fee in an amount that, subject to Subsection
1425	26B-1-310(5), the department sets in accordance with Section 63J-1-504, plus
1426	the cost of the criminal background check described in Section 26B-4-215.
1427	(ii) The department shall notify the Department of Public Safety of each individual
1428	that the department registers for a medical cannabis guardian card.
1429	(c)(i) A minor is eligible for a provisional patient card if:
1430	(A) the minor has a qualifying condition;
1431	(B) the minor's recommending medical provider recommends a medical cannabis
1432	treatment to address the minor's qualifying condition;
1433	(C) one of the minor's parents or legal guardians petitions the Compassionate Use
1434	Board under Section 26B-1-421, and the Compassionate Use Board
1435	recommends department approval of the petition; and
1436	(D) the minor's parent or legal guardian is eligible for a medical cannabis guardian
1437	card under Subsection (2)(b) or designates a caregiver under Subsection (2)(d)
1438	who is eligible for a medical cannabis caregiver card under Section 26B-4-214.
1439	(ii) The department shall automatically issue a provisional patient card to the minor
1440	described in Subsection (2)(c)(i) at the same time the department issues a medical
1441	cannabis guardian card to the minor's parent or legal guardian.
1442	(d) If the parent or legal guardian of a minor described in Subsections (2)(c)(i)(A)
1443	through (C) does not qualify for a medical cannabis guardian card under Subsection
1444	(2)(b), the parent or legal guardian may designate up to two caregivers in accordance
1445	with Subsection 26B-4-214(1)(c) to ensure that the minor has adequate and safe
1446	access to the recommended medical cannabis treatment.
1447	(3)(a) An individual who is eligible for a medical cannabis card described in Subsection
1448	(2)(a) or (b) shall submit an application for a medical cannabis card to the department:
1449	(i) through an electronic application connected to the state electronic verification
1450	system;
1451	(ii) with the recommending medical provider; and
1452	(iii) with information including:
1453	(A) the applicant's name, gender, age, and address;
1454	(B) the number of the applicant's government issued photo identification;
1455	(C) for a medical cannabis guardian card, the name, gender, and age of the minor
1456	receiving a medical cannabis treatment under the cardholder's medical cannabis

1457	guardian card; and
1458	(D) for a provisional patient card, the name of the minor's parent or legal guardian
1459	who holds the associated medical cannabis guardian card.
1460	(b) The department shall ensure that a medical cannabis card the department issues
1461	under this section contains the information described in Subsection (3)(a)(iii).
1462	(c)(i) If a recommending medical provider determines that, because of age, illness, or
1463	disability, a medical cannabis patient cardholder requires assistance in
1464	administering the medical cannabis treatment that the recommending medical
1465	provider recommends, the recommending medical provider may indicate the
1466	cardholder's need in the state electronic verification system, either directly or[, for
1467	a limited medical provider,] through the order described in Subsections [
1468	<del>26B-4-204(1)(c) and (d)</del> ] <u>26B-4-204(1)(b) and (c)</u> .
1469	(ii) If a recommending medical provider makes the indication described in
1470	Subsection (3)(c)(i):
1471	(A) the department shall add a label to the relevant medical cannabis patient card
1472	indicating the cardholder's need for assistance;
1473	(B) any adult who is 18 years old or older and who is physically present with the
1474	cardholder at the time the cardholder needs to use the recommended medical
1475	cannabis treatment may handle the medical cannabis treatment and any
1476	associated medical cannabis device as needed to assist the cardholder in
1477	administering the recommended medical cannabis treatment; and
1478	(C) an individual of any age who is physically present with the cardholder in the
1479	event of an emergency medical condition, as that term is defined in Section
1480	31A-1-301, may handle the medical cannabis treatment and any associated
1481	medical cannabis device as needed to assist the cardholder in administering the
1482	recommended medical cannabis treatment.
1483	(iii) A non-cardholding individual acting under Subsection (3)(c)(ii)(B) or (C) may
1484	not:
1485	(A) ingest or inhale medical cannabis;
1486	(B) possess, transport, or handle medical cannabis or a medical cannabis device
1487	outside of the immediate area where the cardholder is present or with an intent
1488	other than to provide assistance to the cardholder; or
1489	(C) possess, transport, or handle medical cannabis or a medical cannabis device
1490	when the cardholder is not in the process of being dosed with medical cannabis

1491	(4) To recommend a medical cannabis treatment to a patient or to renew a
1492	recommendation, a recommending medical provider shall:]
1493	[(a) visit with the patient face-to-face for an initial recommendation unless the patient:]
1494	[(i) prefers a virtual visit; and]
1495	[(ii)(A) is on hospice or has a terminal illness according to the patient's medical
1496	provider; or]
1497	[(B) is a resident of an assisted living facility, as defined in Section 26B-2-201, or
1498	a nursing care facility, as defined in Section 26B-2-201;]
1499	[(b)] (4)(a) Except as provided in Subsection (4)(b), a recommending medical provider may not
	recommend medical cannabis to a patient through a virtual visit.
1500	(b) A recommending medical provider may recommend medical cannabis to a patient
1501	through a virtual visit if the patient:
1502	(i) is on hospice or has a terminal illness according to the patient's medical provider;
1503	(ii) is a resident of an assisted living facility, as defined in Section 26B-2-201, or a
1504	nursing care facility, as defined in Section 26B-2-201;
1505	(iii) has previously received a medical cannabis recommendation from the
1506	recommending medical provider through a face-to-face visit; or
1507	(iv) is a current patient of the recommending medical provider and has met with the
1508	recommending medical provider face-to-face previously.
1509	(c) A recommending medical provider shall:
1510	(i) before recommending or renewing a recommendation for medical cannabis in a
1511	medicinal dosage form or a cannabis product in a medicinal dosage form:
1512	[(i)] (A) verify the patient's and, for a minor patient, the minor patient's parent or
1513	legal guardian's government issued photo identification described in
1514	Subsection (3)(a);
1515	[(ii)] (B) review any record related to the patient and, for a minor patient, the
1516	patient's parent or legal guardian [in:] accessible to the recommending medical
1517	provider including in the controlled substance database created in Section
1518	<u>58-37f-201; and</u>
1519	[(A) for a qualified medical provider, the state electronic verification system; and]
1520	[(B) the controlled substance database created in Section 58-37f-201; and]
1521	[(iii)] (C) consider the recommendation in light of the patient's qualifying
1522	condition, history of substance use or opioid use disorder, and history of
1523	medical cannabis and controlled substance use during a visit with the patient:

1524	and
1525	[(e)] (ii) state in the recommending medical provider's recommendation that the
1526	patient:
1527	[(i)] (A) suffers from a qualifying condition, including the type of qualifying
1528	condition; and
1529	[(ii)] (B) may benefit from treatment with cannabis in a medicinal dosage form of
1530	a cannabis product in a medicinal dosage form.
1531	(5)(a) Except as provided in Subsection (5)(b) or (c), a medical cannabis card that the
1532	department issues under this section is valid for the lesser of:
1533	(i) an amount of time that the recommending medical provider determines; or
1534	(ii) one year from the day the card is issued.
1535	(b)(i) A medical cannabis card that the department issues in relation to a terminal
1536	illness described in Section 26B-4-203 expires after one year.
1537	(ii) The recommending medical provider may revoke a recommendation that the
1538	provider made in relation to a terminal illness described in Section 26B-4-203 if
1539	the medical cannabis cardholder no longer has the terminal illness.
1540	(c) A medical cannabis card that the department issues in relation to acute pain as
1541	described in Section 26B-4-203 expires 30 days after the day on which the
1542	department first issues a conditional or full medical cannabis card.
1543	(6)(a) A medical cannabis patient card or a medical cannabis guardian card is renewable
1544	if:
1545	(i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a)
1546	or (b); or
1547	(ii) the cardholder received the medical cannabis card through the recommendation of
1548	the Compassionate Use Board under Section 26B-1-421.
1549	(b) The recommending medical provider who made the underlying recommendation for
1550	the card of a cardholder described in Subsection (6)(a) may renew the cardholder's
1551	card through phone or video conference with the cardholder, at the recommending
1552	medical provider's discretion.
1553	(c) Before having access to a renewed card, a cardholder under Subsection (2)(a) or (b)
1554	shall pay to the department a renewal fee in an amount that:
1555	(i) subject to Subsection 26B-1-310(5), the department sets in accordance with
1556	Section 63J-1-504; and
1557	(ii) may not exceed the cost of the relatively lower administrative burden of renewal

1558	in comparison to the original application process.
1559	(d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional
1560	patient card renews automatically at the time the minor's parent or legal guardian
1561	renews the parent or legal guardian's associated medical cannabis guardian card.
1562	(7)(a) A cardholder under this section shall carry the cardholder's valid medical cannabis
1563	card with the patient's name.
1564	(b)(i) A medical cannabis patient cardholder or a provisional patient cardholder may
1565	purchase, in accordance with this part and the recommendation underlying the
1566	card, cannabis in a medicinal dosage form, a cannabis product in a medicinal
1567	dosage form, or a medical cannabis device.
1568	(ii) A cardholder under this section may possess or transport, in accordance with this
1569	part and the recommendation underlying the card, cannabis in a medicinal dosage
1570	form, a cannabis product in a medicinal dosage form, or a medical cannabis
1571	device.
1572	(iii) To address the qualifying condition underlying the medical cannabis treatment
1573	recommendation:
1574	(A) a medical cannabis patient cardholder or a provisional patient cardholder mag
1575	use medical cannabis or a medical cannabis device; and
1576	(B) a medical cannabis guardian cardholder may assist the associated provisional
1577	patient cardholder with the use of medical cannabis or a medical cannabis
1578	device.
1579	(8)(a) The department may revoke a medical cannabis card that the department issues
1580	under this section if:
1581	(i) the recommending medical provider withdraws the medical provider's
1582	recommendation for medical cannabis; or
1583	(ii) the cardholder:
1584	(A) violates this part; or
1585	(B) is convicted under state or federal law of, after March 17, 2021, a drug
1586	distribution offense.
1587	(b) The department may not refuse to issue a medical cannabis card to a patient solely
1588	based on a prior revocation under Subsection (8)(a)(i).
1589	(9) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah
1590	Administrative Rulemaking Act, a process to provide information regarding the
1591	following to an individual receiving a medical cannabis card:

1592	(a) risks associated with medical cannabis treatment;
1593	(b) the fact that a condition's listing as a qualifying condition does not suggest that
1594	medical cannabis treatment is an effective treatment or cure for that condition, as
1595	described in Subsection 26B-4-203(1); and
1596	(c) other relevant warnings and safety information that the department determines.
1597	(10) The department may establish procedures by rule, in accordance with Title 63G,
1598	Chapter 3, Utah Administrative Rulemaking Act, to implement the application and
1599	issuance provisions of this section.
1600	(11)(a) The department shall establish by rule, in accordance with Title 63G, Chapter 3,
1601	Utah Administrative Rulemaking Act, a process to allow an individual from another
1602	state to register with the department in order to purchase medical cannabis or a
1603	medical cannabis device from a medical cannabis pharmacy while the individual is
1604	visiting the state.
1605	(b) The department may only provide the registration process described in Subsection
1606	(11)(a):
1607	(i) to a nonresident patient; and
1608	(ii) for no more than two visitation periods per calendar year of up to 21 calendar
1609	days per visitation period.
1610	(12)(a) A person may submit to the department a request to conduct a research study
1611	using medical cannabis cardholder data that the state electronic verification system
1612	contains.
1613	(b) The department shall review a request described in Subsection (12)(a) to determine
1614	whether an institutional review board, as that term is defined in Section 26B-4-201,
1615	could approve the research study.
1616	(c) At the time an individual applies for a medical cannabis card, the department shall
1617	notify the individual:
1618	(i) of how the individual's information will be used as a cardholder;
1619	(ii) that by applying for a medical cannabis card, unless the individual withdraws
1620	consent under Subsection (12)(d), the individual consents to the use of the
1621	individual's information for external research; and
1622	(iii) that the individual may withdraw consent for the use of the individual's
1623	information for external research at any time, including at the time of application
1624	(d) An applicant may, through the medical cannabis card application, and a medical
1625	cannabis cardholder may, through the state central patient portal, withdraw the

1626	applicant's or cardholder's consent to participate in external research at any time.
1627	(e) The department may release, for the purposes of a study described in this Subsection
1628	(12), information about a cardholder under this section who consents to participate
1629	under Subsection (12)(c).
1630	(f) If an individual withdraws consent under Subsection (12)(d), the withdrawal of
1631	consent:
1632	(i) applies to external research that is initiated after the withdrawal of consent; and
1633	(ii) does not apply to research that was initiated before the withdrawal of consent.
1634	(g) The department may establish standards for a medical research study's validity, by
1635	rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking
1636	Act.
1637	(13) The department shall record the issuance or revocation of a medical cannabis card
1638	under this section in the controlled substance database.
1639	Section 13. Section <b>26B-4-214</b> is amended to read:
1640	26B-4-214. Medical cannabis caregiver card Registration Renewal
1641	Revocation.
1642	(1)(a) A cardholder described in Section 26B-4-213 may designate, through the state
1643	central patient portal, up to two individuals, or an individual and a facility in
1644	accordance with Subsection (1)(b), to serve as a designated caregiver for the
1645	cardholder.
1646	(b)(i) A cardholder described in Section 26B-4-213 may designate one of the
1647	following types of facilities as one of the caregivers described in Subsection (1)(a):
1648	(A) for a patient or resident, an assisted living facility, as that term is defined in
1649	Section 26B-2-201;
1650	(B) for a patient or resident, a nursing care facility, as that term is defined in
1651	Section 26B-2-201; or
1652	(C) for a patient, a general acute hospital, as that term is defined in Section
1653	26B-2-201.
1654	(ii) A facility may:
1655	(A) assign one or more employees to assist patients with medical cannabis
1656	treatment under the caregiver designation described in this Subsection (1)(b);
1657	and
1658	(B) receive a medical cannabis shipment from a medical cannabis pharmacy or a
1659	medical cannabis courier on behalf of the medical cannabis cardholder within

1660	the facility who designated the facility as a caregiver.
1661	(iii) The department shall make rules to regulate the practice of facilities and facility
1662	employees serving as designated caregivers under this Subsection (1)(b).
1663	(c) A parent or legal guardian described in Subsection 26B-4-213(2)(d), in consultation
1664	with the minor and the minor's [qualified medical provider] recommending medical
1665	provider, may designate, through the state central patient portal, up to two individuals
1666	to serve as a designated caregiver for the minor, if the department determines that the
1667	parent or legal guardian is not eligible for a medical cannabis guardian card under
1668	Section 26B-4-213.
1669	(d)(i) Upon the entry of a caregiver designation under Subsection (1)(c) by a patient
1670	with a terminal illness described in Section 26B-4-203, the department shall issue
1671	to the designated caregiver an electronic conditional medical cannabis caregiver
1672	card, in accordance with this Subsection (1)(d).
1673	(ii) A conditional medical cannabis caregiver card is valid for the lesser of:
1674	(A) 60 days; or
1675	(B) the day on which the department completes the department's review and issues
1676	a medical cannabis caregiver card under Subsection (1)(a), denies the patient's
1677	medical cannabis caregiver card application, or revokes the conditional
1678	medical cannabis caregiver card under 26B-4-246.
1679	(iii) The department may issue a conditional medical cannabis card to an individual
1680	applying for a medical cannabis patient card for which approval of the
1681	Compassionate Use Board is not required.
1682	(iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and
1683	obligations under law applicable to a holder of the medical cannabis card for
1684	which the individual applies and for which the department issues the conditional
1685	medical cannabis card.
1686	(2) An individual that the department registers as a designated caregiver under this section
1687	and a facility described in Subsection (1)(b):
1688	(a) for an individual designated caregiver, may carry a valid medical cannabis caregiver
1689	card;
1690	(b) in accordance with this part, may purchase, possess, transport, or assist the patient in
1691	the use of cannabis in a medicinal dosage form, a cannabis product in a medicinal
1692	dosage form, or a medical cannabis device on behalf of the designating medical
1693	cannabis cardholder

1694	(c) may not charge a fee to an individual to act as the individual's designated caregiver
1695	or for a service that the designated caregiver provides in relation to the role as a
1696	designated caregiver; and
1697	(d) may accept reimbursement from the designating medical cannabis cardholder for
1698	direct costs the designated caregiver incurs for assisting with the designating
1699	cardholder's medicinal use of cannabis.
1700	(3)(a) The department shall:
1701	(i) within 15 days after the day on which an individual submits an application in
1702	compliance with this section, issue a medical cannabis card to the applicant if the
1703	applicant:
1704	(A) is designated as a caregiver under Subsection (1);
1705	(B) is eligible for a medical cannabis caregiver card under Subsection (4); and
1706	(C) complies with this section; and
1707	(ii) notify the Department of Public Safety of each individual that the department
1708	registers as a designated caregiver.
1709	(b) The department shall ensure that a medical cannabis caregiver card contains the
1710	information described in Subsections (5)(b) and (3)(c)(i).
1711	(c) If a cardholder described in Section 26B-4-213 designates an individual as a
1712	caregiver who already holds a medical cannabis caregiver card, the individual with
1713	the medical cannabis caregiver card:
1714	(i) shall report to the department the information required of applicants under
1715	Subsection (5)(b) regarding the new designation;
1716	(ii) if the individual makes the report described in Subsection (3)(c)(i), is not required
1717	to file an application for another medical cannabis caregiver card;
1718	(iii) may receive an additional medical cannabis caregiver card in relation to each
1719	additional medical cannabis patient who designates the caregiver; and
1720	(iv) is not subject to an additional background check.
1721	(4) An individual is eligible for a medical cannabis caregiver card if the individual:
1722	(a) is at least 21 years old;
1723	(b) is a Utah resident;
1724	(c) pays to the department a fee in an amount that, subject to Subsection 26B-1-310(5),
1725	the department sets in accordance with Section 63J-1-504, plus the cost of the
1726	criminal background check described in Section 26B-4-215;
1727	(d) signs an acknowledgment stating that the applicant received the information

1728	described in Subsection 26B-4-213(9).
1729	(5) An eligible applicant for a medical cannabis caregiver card shall:
1730	(a) submit an application for a medical cannabis caregiver card to the department
1731	through an electronic application connected to the state electronic verification
1732	system; and
1733	(b) submit the following information in the application described in Subsection (5)(a):
1734	(i) the applicant's name, gender, age, and address;
1735	(ii) the name, gender, age, and address of the cardholder described in Section
1736	26B-4-213 who designated the applicant;
1737	(iii) if a medical cannabis guardian cardholder designated the caregiver, the name,
1738	gender, and age of the minor receiving a medical cannabis treatment in relation to
1739	the medical cannabis guardian cardholder; and
1740	(iv) any additional information that the department requests to assist in matching the
1741	application with the designating medical cannabis patient.
1742	(6) Except as provided in Subsection (6)(b), a medical cannabis caregiver card that the
1743	department issues under this section is valid for the lesser of:
1744	(a) an amount of time that the cardholder described in Section 26B-4-213 who
1745	designated the caregiver determines; or
1746	(b) the amount of time remaining before the card of the cardholder described in Section
1747	26B-4-213 expires.
1748	(7)(a) If a designated caregiver meets the requirements of Subsection (4), the designated
1749	caregiver's medical cannabis caregiver card renews automatically at the time the
1750	cardholder described in Section 26B-4-213 who designated the caregiver:
1751	(i) renews the cardholder's card; and
1752	(ii) renews the caregiver's designation, in accordance with Subsection (7)(b).
1753	(b) The department shall provide a method in the card renewal process to allow a
1754	cardholder described in Section 26B-4-213 who has designated a caregiver to:
1755	(i) signify that the cardholder renews the caregiver's designation;
1756	(ii) remove a caregiver's designation; or
1757	(iii) designate a new caregiver.
1758	(8) The department shall record the issuance or revocation of a medical cannabis card under
1759	this section in the controlled substance database.
1760	Section 14. Section 26B-4-231 is amended to read:

26B-4-231 . Partial filling -- Pharmacy medical provider directions of use.

1777

1778

1779

1780

1781

1782

17831784

17851786

1787

1788

1789

1790

1791

1792

1793

1794

1795

- 1762 (1) As used in this section, "partially fill" means to provide less than the full amount of cannabis or cannabis product that the recommending medical provider recommends, if the recommending medical provider recommended specific dosing guidelines.
- 1765 (2) A pharmacy medical provider may partially fill a recommendation for a medical cannabis treatment at the request of the recommending medical provider who issued the medical cannabis treatment recommendation or the medical cannabis cardholder.
- 1768 (3) The department shall make rules, in collaboration with the Division of Professional
  1769 Licensing and the Board of Pharmacy and in accordance with Title 63G, Chapter 3, Utah
  1770 Administrative Rulemaking Act, specifying how to record the date, quantity supplied,
  1771 and quantity remaining of a partially filled medical cannabis treatment recommendation.
- 1772 (4) A pharmacy medical provider who is a pharmacist may, upon the request of a medical 1773 cannabis cardholder, determine different dosing guidelines, subject to the dosing limits 1774 in Subsection 4-41a-1102(2), to fill the quantity remaining of a partially filled medical 1775 cannabis treatment recommendation if:
  - (a) the pharmacy medical provider determined dosing guidelines for the partial fill under Subsection 4-41a-1102(5) or (6); and
    - (b) the medical cannabis cardholder reports that:
      - (i) the partial fill did not substantially affect the qualifying condition underlying the medical cannabis recommendation; or
      - (ii) the patient experienced an adverse reaction to the partial fill or was otherwise unable to successfully use the partial fill.
  - (5) If a recommending medical provider recommends treatment with medical cannabis but wishes for the pharmacy medical provider to determine directions of use and dosing guidelines:
    - (a) the recommending medical provider shall provide to the pharmacy medical provider, either through the state electronic verification system or through a medical cannabis pharmacy's recording of a recommendation under the order of a [limited medical provider] recommending medical provider, any of the following information that the recommending medical provider feels would be needed to provide appropriate directions of use and dosing guidelines:
      - (i) information regarding the qualifying condition underlying the recommendation;
      - (ii) information regarding prior treatment attempts with medical cannabis; and
      - (iii) portions of the patient's current medication list; and
    - (b) before the relevant medical cannabis cardholder may obtain medical cannabis, the

1796	pharmacy medical provider shall:
1797	(i) review pertinent medical records, including the recommending medical provider
1798	documentation described in Subsection (5)(a); and
1799	(ii) after completing the review described in Subsection (5)(b)(i) and consulting with
1800	the recommending medical provider as needed, determine the best course of
1801	treatment through consultation with the cardholder regarding:
1802	(A) the patient's qualifying condition underlying the recommendation from the
1803	recommending medical provider;
1804	(B) indications for available treatments;
1805	(C) directions of use and dosing guidelines; and
1806	(D) potential adverse reactions.
1807	Section 15. Section 26B-4-245 is amended to read:
1808	26B-4-245 . Purchasing and use limitations.
1809	(1) An individual with a medical cannabis card:
1810	(a) may purchase, in any one 28-day period, up to the legal dosage limit of:
1811	(i) unprocessed cannabis in a medicinal dosage form; and
1812	(ii) a cannabis product in a medicinal dosage form;
1813	(b) may not purchase:
1814	(i) except as provided in Subsection (2), more medical cannabis than described in
1815	Subsection (1)(a); or
1816	(ii) if the relevant recommending medical provider did not recommend directions of
1817	use and dosing guidelines, until the individual consults with the pharmacy medical
1818	provider in accordance with Subsection 26B-4-231(5), any medical cannabis; and
1819	(c) may not use a route of administration that the relevant recommending medical
1820	provider or the pharmacy medical provider, in accordance with Subsection 26B-4-231
1821	(5), has not recommended.
1822	(2)(a) A [qualified medical provider] recommending medical provider may petition the
1823	department to waive the 28-day period limit described in Subsection (1)(a) for a
1824	medical cannabis cardholder if the medical cannabis cardholder:
1825	(i) has been diagnosed with a terminal illness;
1826	(ii) has a life expectancy of six months or less; and
1827	(iii) needs the waiver for palliative purposes.
1828	(b) The department shall:
1829	(i) consult with the Compassionate Use Board to determine whether the waiver

1830	should be granted;
1831	(ii) issue a response to the petition within 10 days from the day on which the petition
1832	is received.
1833	(c) The department may waive the 28-day period limit for no more than 180 days.
1834	(d) A petition described in this Subsection (2) may be combined with the petition
1835	described in Subsection 26B-1-421(6).
1836	Section 16. Section 53B-17-903 is amended to read:
1837	53B-17-903. Education in pain treatment.
1838	The University of Utah School of Medicine shall ensure that any licensed physicians
1839	who oversee fellowship training to specialize in pain treatment are [qualified medical providers]
1840	recommending medical providers, as that term is defined in Section 26B-4-201.
1841	Section 17. Section <b>58-1-513</b> is enacted to read:
1842	$\underline{58\text{-}1\text{-}513}$ . Recommending medical provider cannabis advertisement Payment
1843	restriction Unprofessional conduct.
1844	(1) As used in this section:
1845	(a) "Recommending medical provider" means the same as that term is defined in Section
1846	<u>26B-4-201.</u>
1847	(b) "Targeted marketing" means the same as that term is defined in Section 26B-4-201.
1848	(2)(a) Except as provided in Subsections (2)(b) and (c), a person may not advertise that
1849	the person or the person's employee recommends a medical cannabis treatment.
1850	(b) Notwithstanding Subsection (2)(a) and Section 4-41a-109, a recommending medical
1851	provider, medical clinic, or medical office that employs a recommending medical
1852	provider may advertise only the following:
1853	(i) a green cross;
1854	(ii) the provider's or clinic's name and logo;
1855	(iii) a qualifying condition that the individual treats;
1856	(iv) that the recommending medical provider, medical clinic, or medical office
1857	evaluates patients for medical cannabis recommendations;
1858	(v) a scientific study regarding medical cannabis use; or
1859	(vi) contact information.
1860	(c) Notwithstanding Subsection (2)(a) and Section 4-41a-109, a recommending medical
1861	provider, medical clinic, or medical office that employs a recommending medical
1862	provider may engage in targeted marketing, as determined by the Department of
1863	Health and Human Services through rule, for advertising medical cannabis

1864	recommendation services.
1865	(3)(a) A recommending medical provider may not:
1866	(i) receive any compensation or benefit for the recommending medical provider's
1867	medical cannabis treatment recommendation from:
1868	(A) a cannabis production establishment or an owner, officer, director, board
1869	member, employee, or agent of a cannabis production establishment;
1870	(B) a medical cannabis pharmacy or an owner, officer, director, board member,
1871	employee, or agent of a medical cannabis pharmacy; or
1872	(C) a recommending medical provider or pharmacy medical provider; or
1873	(ii) provide a medical cannabis recommendation at a medical clinic or medical office
1874	that is violating the advertising limitations described in Subsection (2).
1875	(b) A violation of Subsection (3)(a) is unprofessional conduct.
1876	Section 18. Section <b>58-5a-102</b> is amended to read:
1877	58-5a-102 . Definitions.
1878	In addition to the definitions under Section 58-1-102, as used in this chapter:
1879	(1) "Assisted living facility" means the same as that term is defined in Section 26B-2-201.
1880	(2) "Board" means the Podiatric Physician Board created in Section 58-5a-201.
1881	(3) "Indirect supervision" means the same as that term is defined by the division by rule
1882	made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
1883	(4) "Medical assistant" means an unlicensed individual working under the indirect
1884	supervision of a licensed podiatric physician and engaging in specific tasks assigned by
1885	the licensed podiatric physician in accordance with the standards and ethics of the
1886	podiatry profession.
1887	(5) "Practice of podiatry" means, subject to Section 58-5a-103, the diagnosis and treatment
1888	of conditions affecting the human foot and ankle and their manifestations of systemic
1889	conditions, and wound debridement on the limbs and torso, by all appropriate and lawful
1890	means.
1891	(6) "Unlawful conduct" includes:
1892	(a) the conduct that constitutes unlawful conduct under Section 58-1-501; and
1893	(b) for an individual who is not licensed under this chapter:
1894	(i) using the title or name podiatric physician, podiatrist, podiatric surgeon, foot
1895	doctor, foot specialist, or D.P.M.; or
1896	(ii) implying or representing that the individual is qualified to practice podiatry.
1897	(7)(a) "Unprofessional conduct" includes, for an individual licensed under this chapter:

1898	(i) the conduct that constitutes unprofessional conduct under Section 58-1-501;
1899	(ii) communicating to a third party, without the consent of the patient, information
1900	the individual acquires in treating the patient, except as necessary for professional
1901	consultation regarding treatment of the patient;
1902	(iii) allowing the individual's name or license to be used by an individual who is not
1903	licensed to practice podiatry under this chapter;
1904	(iv) except as described in Section 58-5a-306, employing, directly or indirectly, any
1905	unlicensed individual to practice podiatry;
1906	(v) using alcohol or drugs, to the extent the individual's use of alcohol or drugs
1907	impairs the individual's ability to practice podiatry;
1908	(vi) unlawfully prescribing, selling, or giving away any prescription drug, including
1909	controlled substances, as defined in Section 58-37-2;
1910	(vii) gross incompetency in the practice of podiatry;
1911	(viii) willfully and intentionally making a false statement or entry in hospital records,
1912	medical records, or reports;
1913	(ix) willfully making a false statement in reports or claim forms to governmental
1914	agencies or insurance companies with the intent to secure payment not rightfully
1915	due;
1916	(x) willfully using false or fraudulent advertising;
1917	(xi) conduct the division defines as unprofessional conduct by rule made in
1918	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act;
1919	(xii) falsely making an entry in, or altering, a medical record with the intent to
1920	conceal:
1921	(A) a wrongful or negligent act or omission of an individual licensed under this
1922	chapter or an individual under the direction or control of an individual licensed
1923	under this chapter; or
1924	(B) conduct described in Subsections (7)(a)(i) through (xi) or Subsection 58-1-501
1925	(1); or
1926	(xiii) violating the requirements of Title 26B, Chapter 4, Part 2, Cannabinoid
1927	Research and Medical Cannabis.
1928	(b) "Unprofessional conduct" does not include, in accordance with Title 26B, Chapter 4,
1929	Part 2, Cannabinoid Research and Medical Cannabis, when [registered as a
1930	qualified medical provider or acting as a limited medical provider, as those terms are]
1931	acting as a recommending medical provider, as that term is defined in Section

1932	26B-4-201, recommending the use of medical cannabis within the scope of a practice
1933	of podiatry.
1934	Section 19. Section <b>58-31b-305</b> is amended to read:
1935	58-31b-305 . Term of license Expiration Renewal.
1936	(1)(a) The division shall issue each license or certification under this chapter in
1937	accordance with a two-year renewal cycle established by rule.
1938	(b) The division may by rule extend or shorten a renewal period by as much as one year
1939	to stagger the renewal cycles the division administers.
1940	(2) The division shall renew the license of a licensee who, at the time of renewal:
1941	(a) completes and submits an application for renewal in a form prescribed by the
1942	division;
1943	(b) pays a renewal fee established by the division under Section 63J-1-504;
1944	(c) views a suicide prevention video described in Section 58-1-601 and submits proof in
1945	the form required by the division; and
1946	(d) meets continuing competency requirements as established by rule.
1947	(3) In addition to the renewal requirements under Subsection (2), a person licensed as an
1948	advanced practice registered nurse shall be currently certified by a program approved by
1949	the division in collaboration with the board and submit evidence satisfactory to the
1950	division of that qualification or if licensed prior to July 1, 1992, meet the requirements
1951	established by rule.
1952	(4) In addition to the requirements described in Subsections (2) and (3), an advanced
1953	practice registered nurse licensee specializing in psychiatric mental health nursing who,
1954	as of the day on which the division originally issued the licensee's license had not
1955	completed the division's clinical practice requirements in psychiatric and mental health
1956	nursing, shall, to qualify for renewal:
1957	(a) if renewing less than two years after the day on which the division originally issued
1958	the license, demonstrate satisfactory progress toward completing the clinical practice
1959	requirements; or
1960	(b) have completed the clinical practice requirements.
1961	(5) Each license or certification automatically expires on the expiration date shown on the
1962	license or certification unless renewed in accordance with Section 58-1-308.
1963	[(6) The division shall accept and apply toward an hour requirement that the division
1964	establishes under Subsection (2)(d) continuing education that an advanced practice
1965	registered nurse completes in accordance with Section 26B-4-204.]

1966	Section 20. Section <b>58-31b-502</b> is amended to read:
1967	58-31b-502 . Unprofessional conduct.
1968	(1) "Unprofessional conduct" includes:
1969	(a) failure to safeguard a patient's right to privacy as to the patient's person, condition,
1970	diagnosis, personal effects, or any other matter about which the licensee is privileged
1971	to know because of the licensee's or person with a certification's position or practice
1972	as a nurse or practice as a medication aide certified;
1973	(b) failure to provide nursing service or service as a medication aide certified in a
1974	manner that demonstrates respect for the patient's human dignity and unique personal
1975	character and needs without regard to the patient's race, religion, ethnic background,
1976	socioeconomic status, age, sex, or the nature of the patient's health problem;
1977	(c) engaging in sexual relations with a patient during any:
1978	(i) period when a generally recognized professional relationship exists between the
1979	person licensed or certified under this chapter and the patient; or
1980	(ii) extended period when a patient has reasonable cause to believe a professional
1981	relationship exists between the person licensed or certified under the provisions of
1982	this chapter and the patient;
1983	(d)(i) as a result of any circumstance under Subsection (1)(c), exploiting or using
1984	information about a patient or exploiting the licensee's or the person with a
1985	certification's professional relationship between the licensee or holder of a
1986	certification under this chapter and the patient; or
1987	(ii) exploiting the patient by use of the licensee's or person with a certification's
1988	knowledge of the patient obtained while acting as a nurse or a medication aide
1989	certified;
1990	(e) unlawfully obtaining, possessing, or using any prescription drug or illicit drug;
1991	(f) unauthorized taking or personal use of nursing supplies from an employer;
1992	(g) unauthorized taking or personal use of a patient's personal property;
1993	(h) unlawful or inappropriate delegation of nursing care;
1994	(i) failure to exercise appropriate supervision of persons providing patient care services
1995	under supervision of the licensed nurse;
1996	(j) employing or aiding and abetting the employment of an unqualified or unlicensed
1997	person to practice as a nurse;
1998	(k) failure to file or record any medical report as required by law, impeding or

obstructing the filing or recording of such a report, or inducing another to fail to file

2000		or record such a report;
2001		(l) breach of a statutory, common law, regulatory, or ethical requirement of
2002		confidentiality with respect to a person who is a patient, unless ordered by a court;
2003		(m) failure to pay a penalty imposed by the division;
2004		(n) violating Section 58-31b-801;
2005		(o) violating the dispensing requirements of Section 58-17b-309 or Chapter 17b, Part 8,
2006		Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic
2007		Pharmacy, if applicable;
2008		(p) performing or inducing an abortion in violation of the requirements of Section
2009		76-7-302 or Section 76-7a-201, regardless of whether the person licensed or certified
2010		under the provisions of this chapter is found guilty of a crime in connection with the
2011		violation;
2012		(q) falsely making an entry in, or altering, a medical record with the intent to conceal:
2013		(i) a wrongful or negligent act or omission of an individual licensed under this
2014		chapter or an individual under the direction or control of an individual licensed
2015		under this chapter; or
2016		(ii) conduct described in Subsections (1)(a) through (n) or Subsection 58-1-501(1);
2017		(r) violating the requirements of Title 26B, Chapter 4, Part 2, Cannabinoid Research and
2018		Medical Cannabis; or
2019		(s) for an advance practice registered nurse, designating a child as do not resuscitate
2020		without parental consent.
2021	(2)	"Unprofessional conduct" does not include, in accordance with Title 26B, Chapter 4,
2022		Part 2, Cannabinoid Research and Medical Cannabis, when [registered as a qualified
2023		medical provider, or acting as a limited medical provider, as those terms are] acting as a
2024		recommending medical provider, as that term is defined in Section 26B-4-201,
2025		recommending the use of medical cannabis.
2026	(3)	Notwithstanding Subsection (2), the division, in consultation with the board and in
2027		accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall
2028		define unprofessional conduct for an advanced practice registered nurse described in
2029		Subsection (2).
2030		Section 21. Section <b>58-67-304</b> is amended to read:
2031		58-67-304 . License renewal requirements.
2032	(1)	As a condition precedent for license renewal, each licensee shall, during each two-year
2033		licensure cycle or other cycle defined by division rule:

- 2034 (a) complete qualified continuing professional education requirements in accordance
  2035 with the number of hours and standards defined by division rule made in
  2036 collaboration with the board;
  2037 (b) appoint a contact person for access to medical records and an alternate contact
  2038 person for access to medical records in accordance with Subsection 58-67-302(1)(i);
  - (c) if the licensee practices medicine in a location with no other persons licensed under this chapter, provide some method of notice to the licensee's patients of the identity and location of the contact person and alternate contact person for the licensee; and
  - (d) if the licensee is an associate physician licensed under Section 58-67-302.8, successfully complete the educational methods and programs described in Subsection 58-67-807(4).
  - (2) If a renewal period is extended or shortened under Section 58-67-303, the continuing education hours required for license renewal under this section are increased or decreased proportionally.
  - (3)(a) An application to renew a license under this chapter shall:
    - (i) require a physician to answer the following question: "Do you perform elective abortions in Utah in a location other than a hospital?"; and
    - (ii) immediately following the question, contain the following statement: "For purposes of the immediately preceding question, elective abortion means an abortion other than one of the following: removal of a dead fetus, removal of an ectopic pregnancy, an abortion that is necessary to avert the death of a woman, an abortion that is necessary to avert a serious physical risk of substantial impairment of a major bodily function of a woman, an abortion of a fetus that has a defect that is uniformly diagnosable and uniformly lethal, or an abortion where the woman is pregnant as a result of rape or incest."
    - (b) The statement in Subsection (3)(a)(ii) shall be modified, if necessary, to ensure compliance with the definitions and requirements of Title 76, Chapter 7, Part 3, Abortion, and Title 76, Chapter 7a, Abortion Prohibition.
  - (4) In order to assist the Department of Health and Human Services in fulfilling the department's responsibilities relating to the licensing of a health care facility and the enforcement of Title 76, Chapter 7, Part 3, Abortion, and Title 76, Chapter 7a, Abortion Prohibition, if a physician responds positively to the question described in Subsection (3)(a)(i) the division shall, within 30 days after the day on which the division renews the physician's license under this chapter, inform the Department of Health and Human

2068		Services in writing:
2069		(a) of the name and business address of the physician; and
2070		(b) that the physician responded positively to the question described in Subsection
2071		(3)(a)(i).
2072	(5)	The division shall accept and apply toward the hour requirement in Subsection (1)(a)
2073		any continuing education that a physician completes in accordance with [Sections
2074		<del>26B-4-204 and</del> ] <u>Section</u> 26B-4-219.
2075		Section 22. Section <b>58-67-502</b> is amended to read:
2076		58-67-502 . Unprofessional conduct.
2077	(1)	"Unprofessional conduct" includes, in addition to the definition in Section 58-1-501:
2078		(a) using or employing the services of any individual to assist a licensee in any manner
2079		not in accordance with the generally recognized practices, standards, or ethics of the
2080		profession, state law, or division rule;
2081		(b) making a material misrepresentation regarding the qualifications for licensure under
2082		Section 58-67-302.7 or 58-67-302.8;
2083		(c) violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical
2084		Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable;
2085		(d) violating the requirements of Title 26B, Chapter 4, Part 2, Cannabinoid Research and
2086		Medical Cannabis;
2087		(e) performing or inducing an abortion in violation of the requirements of Section
2088		76-7-302 or Section 76-7a-201, regardless of whether the individual licensed under
2089		this chapter is found guilty of a crime in connection with the violation;
2090		(f) falsely making an entry in, or altering, a medical record with the intent to conceal:
2091		(i) a wrongful or negligent act or omission of an individual licensed under this
2092		chapter or an individual under the direction or control of an individual licensed
2093		under this chapter; or
2094		(ii) conduct described in Subsections (1)(a) through (e) or Subsection 58-1-501(1);
2095		(g) performing, or causing to be performed, upon an individual who is less than 18 years
2096		old:
2097		(i) a primary sex characteristic surgical procedure; or
2098		(ii) a secondary sex characteristic surgical procedure; or
2099		(h) designating a child as do not resuscitate without parental consent.
2100	(2)	"Unprofessional conduct" does not include:
2101		(a) in compliance with Section 58-85-103:

2102	(i) obtaining an investigational drug or investigational device;
2103	(ii) administering the investigational drug to an eligible patient; or
2104	(iii) treating an eligible patient with the investigational drug or investigational device;
2105	or
2106	(b) in accordance with Title 26B, Chapter 4, Part 2, Cannabinoid Research and Medical
2107	Cannabis:
2108	(i) when [registered as a qualified medical provider or acting as a limited medical
2109	provider, as those terms are ] acting as a recommending medical provider, as that
2110	term is defined in Section 26B-4-201, recommending the use of medical cannabis;
2111	or
2112	(ii) when registered as a pharmacy medical provider, as that term is defined in
2113	Section 26B-4-201, providing pharmacy medical provider services in a medical
2114	cannabis pharmacy.
2115	(3) Notwithstanding Subsection (2)(b), the division, in consultation with the board and in
2116	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall
2117	define unprofessional conduct for a physician described in Subsection (2)(b).
2118	Section 23. Section <b>58-68-304</b> is amended to read:
2119	58-68-304 . License renewal requirements.
2120	(1) As a condition precedent for license renewal, each licensee shall, during each two-year
2121	licensure cycle or other cycle defined by division rule:
2122	(a) complete qualified continuing professional education requirements in accordance
2123	with the number of hours and standards defined by division rule in collaboration with
2124	the board;
2125	(b) appoint a contact person for access to medical records and an alternate contact
2126	person for access to medical records in accordance with Subsection 58-68-302(1)(i);
2127	(c) if the licensee practices osteopathic medicine in a location with no other persons
2128	licensed under this chapter, provide some method of notice to the licensee's patients
2129	of the identity and location of the contact person and alternate contact person for
2130	access to medical records for the licensee in accordance with Subsection
2131	58-68-302(1)(j); and
2132	(d) if the licensee is an associate physician licensed under Section 58-68-302.5,
2133	successfully complete the educational methods and programs described in Subsection
2134	58-68-807(4).
2135	(2) If a renewal period is extended or shortened under Section 58-68-303, the continuing

2136	education hours required for license renewal under this section are increased or
2137	decreased proportionally.
2138	(3)(a) An application to renew a license under this chapter shall:
2139	(i) require a physician to answer the following question: "Do you perform elective
2140	abortions in Utah in a location other than a hospital?"; and
2141	(ii) immediately following the question, contain the following statement: "For
2142	purposes of the immediately preceding question, elective abortion means an
2143	abortion other than one of the following: removal of a dead fetus, removal of an
2144	ectopic pregnancy, an abortion that is necessary to avert the death of a woman, an
2145	abortion that is necessary to avert a serious physical risk of substantial impairment
2146	of a major bodily function of a woman, an abortion of a fetus that has a defect that
2147	is uniformly diagnosable and uniformly lethal, or an abortion where the woman is
2148	pregnant as a result of rape or incest."
2149	(b) The statement in Subsection (3)(a)(ii) shall be modified, if necessary, to ensure
2150	compliance with the definitions and requirements of Title 76, Chapter 7, Part 3,
2151	Abortion, and Title 76, Chapter 7a, Abortion Prohibition.
2152	(4) In order to assist the Department of Health and Human Services in fulfilling the
2153	department's responsibilities relating to the licensing of a health care facility and the
2154	enforcement of Title 76, Chapter 7, Part 3, Abortion, and Title 76, Chapter 7a, Abortion
2155	Prohibition, if a physician responds positively to the question described in Subsection
2156	(3)(a)(i), the division shall, within 30 days after the day on which it renews the
2157	physician's license under this chapter, inform the Department of Health and Human
2158	Services in writing:
2159	(a) of the name and business address of the physician; and
2160	(b) that the physician responded positively to the question described in Subsection
2161	(3)(a)(i).
2162	(5) The division shall accept and apply toward the hour requirement in Subsection (1)(a)
2163	any continuing education that a physician completes in accordance with [Sections
2164	<del>26B-4-204 and</del> ] <u>Section</u> 26B-4-219.
2165	Section 24. Section <b>58-68-502</b> is amended to read:
2166	58-68-502 . Unprofessional conduct.
2167	(1) "Unprofessional conduct" includes, in addition to the definition in Section 58-1-501:
2168	(a) using or employing the services of any individual to assist a licensee in any manner
2169	not in accordance with the generally recognized practices, standards, or ethics of the

2170		profession, state law, or division rule;
2171	(b)	violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical
2172		Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable;
2173	(c)	making a material misrepresentation regarding the qualifications for licensure under
2174		Section 58-68-302.5;
2175	(d)	violating the requirements of Title 26B, Chapter 4, Part 2, Cannabinoid Research and
2176		Medical Cannabis;
2177	(e)	performing or inducing an abortion in violation of the requirements of Section
2178		76-7-302 or Section 76-7a-201, regardless of whether the individual licensed under
2179		this chapter is found guilty of a crime in connection with the violation;
2180	(f)	falsely making an entry in, or altering, a medical record with the intent to conceal:
2181		(i) a wrongful or negligent act or omission of an individual licensed under this
2182		chapter or an individual under the direction or control of an individual licensed
2183		under this chapter; or
2184		(ii) conduct described in Subsections (1)(a) through (e) or Subsection 58-1-501(1);
2185	(g)	performing or causing to be performed, upon an individual who is less than 18 years
2186		old:
2187		(i) a primary sex characteristic surgical procedure; or
2188		(ii) a secondary sex characteristic surgical procedure; or
2189	(h)	designating a child as do not resuscitate without parental consent.
2190	(2) "U	'nprofessional conduct" does not include:
2191	(a)	in compliance with Section 58-85-103:
2192		(i) obtaining an investigational drug or investigational device;
2193		(ii) administering the investigational drug to an eligible patient; or
2194		(iii) treating an eligible patient with the investigational drug or investigational device;
2195		or
2196	(b)	in accordance with Title 26B, Chapter 4, Part 2, Cannabinoid Research and Medical
2197		Cannabis:
2198		(i) when [registered as a qualified medical provider or acting as a limited medical
2199		provider, as those terms are] acting as a recommending medical provider, as that
2200		term is defined in Section 26B-4-201, recommending the use of medical cannabis;
2201		or
2202		(ii) when registered as a pharmacy medical provider, as that term is defined in
2203		Section 26B-4-201, providing pharmacy medical provider services in a medical

2204	cannabis pharmacy.
2205	(3) Notwithstanding Subsection (2)(b), the division, in consultation with the board and in
2206	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall
2207	define unprofessional conduct for a physician described in Subsection (2)(b).
2208	Section 25. Section 58-70a-303 is amended to read:
2209	58-70a-303 . Term of license Expiration Renewal.
2210	(1)(a) The division shall issue each license under this chapter in accordance with a
2211	two-year renewal cycle established by division rule.
2212	(b) The division may by rule extend or shorten a renewal period by as much as one year
2213	to stagger the renewal cycles it administers.
2214	(2) At the time of renewal, the licensee shall show compliance with continuing education
2215	renewal requirements.
2216	(3) Each license issued under this chapter expires on the expiration date shown on the
2217	license unless renewed in accordance with Section 58-1-308.
2218	[(4) The division shall accept and apply toward an hour requirement that the division
2219	establishes under Subsection (2) continuing education that a physician assistant
2220	completes in accordance with Section 26B-4-204.]
2221	Section 26. Section <b>58-70a-503</b> is amended to read:
2222	58-70a-503 . Unprofessional conduct.
2223	(1) "Unprofessional conduct" includes:
2224	(a) violation of a patient confidence to any person who does not have a legal right and a
2225	professional need to know the information concerning the patient;
2226	(b) knowingly prescribing, selling, giving away, or directly or indirectly administering,
2227	or offering to prescribe, sell, furnish, give away, or administer any prescription drug
2228	except for a legitimate medical purpose upon a proper diagnosis indicating use of that
2229	drug in the amounts prescribed or provided;
2230	(c) prescribing prescription drugs for oneself or administering prescription drugs to
2231	oneself, except those that have been legally prescribed for the physician assistant by a
2232	licensed practitioner and that are used in accordance with the prescription order for
2233	the condition diagnosed;
2234	(d) in a practice that has physician assistant ownership interests, failure to allow a
2235	physician the independent final decision making authority on treatment decisions for
2236	the physician's patient;
2237	(e) violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical

2238	Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable;
2239	(f) falsely making an entry in, or altering, a medical record with the intent to conceal:
2240	(i) a wrongful or negligent act or omission of an individual licensed under this
2241	chapter or an individual under the direction or control of an individual licensed
2242	under this chapter; or
2243	(ii) conduct described in Subsections (1)(a) through (e) or Subsection 58-1-501(1);
2244	(g) violating the requirements of Title 26B, Chapter 4, Part 2, Cannabinoid Research and
2245	Medical Cannabis; or
2246	(h) designating a child as do not resuscitate without parental consent.
2247	(2)(a) "Unprofessional conduct" does not include, in accordance with Title 26B, Chapter
2248	4, Part 2, Cannabinoid Research and Medical Cannabis, when [registered as a
2249	qualified medical provider or acting as a limited medical provider, as those terms are]
2250	acting as a recommending medical provider, as that term is defined in Section
2251	26B-4-201, recommending the use of medical cannabis.
2252	(b) Notwithstanding Subsection (2)(a), the division, in consultation with the board and in
2253	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall
2254	define unprofessional conduct for a physician assistant described in Subsection (2)(a).
2255	Section 27. Section 80-4-109 is amended to read:
2256	80-4-109. Consideration of cannabis during proceedings.
2257	(1) As used in this section:
2258	(a) "Cannabis" means the same as that term is defined in Section 26B-4-201.
2259	(b) "Cannabis product" means the same as that term is defined in Section 26B-4-201.
2260	(c)(i) "Chronic" means repeated or patterned.
2261	(ii) "Chronic" does not mean an isolated incident.
2262	(d) "Directions of use" means the same as that term is defined in Section 26B-4-201.
2263	(e) "Dosing guidelines" means the same as that term is defined in Section 26B-4-201.
2264	(f) "Medical cannabis" means the same as that term is defined in Section 26B-4-201.
2265	(g) "Medical cannabis cardholder" means the same as that term is defined in Section
2266	26B-4-201.
2267	(h) "[Qualified] Recommending medical provider" means the same as that term is
2268	defined in Section 26B-4-201.
2269	(2) In a proceeding under this chapter in which the juvenile court makes a finding,
2270	determination, or otherwise considers an individual's possession or use of medical
2271	cannabis, a cannabis product, or a medical cannabis device, the juvenile court may not

2272	consider or treat the individual's possession or use any differently than the lawful
2273	possession or use of any prescribed controlled substance if:
2274	(a) the individual's possession or use complies with Title 4, Chapter 41a, Cannabis
2275	Production Establishments and Pharmacies;
2276	(b) the individual's possession or use complies with Subsection 58-37-3.7(2) or (3); or
2277	(c)(i) the individual's possession or use complies with Title 26B, Chapter 4, Part 2,
2278	Cannabinoid Research and Medical Cannabis; and
2279	(ii) the individual reasonably complies with the directions of use and dosing
2280	guidelines determined by the individual's [qualified medical provider]
2281	recommending medical provider or through a consultation described in Subsection
2282	26B-4-230(5).
2283	(3) In a proceeding under this chapter, a parent's or guardian's use of cannabis or a cannabis
2284	product is not abuse or neglect of a child unless there is evidence showing that:
2285	(a) the child is harmed because of the child's inhalation or ingestion of cannabis, or
2286	because of cannabis being introduced to the child's body in another manner; or
2287	(b) the child is at an unreasonable risk of harm because of chronic inhalation or
2288	ingestion of cannabis or chronic introduction of cannabis to the child's body in
2289	another manner.
2290	(4) Unless there is harm or an unreasonable risk of harm to the child as described in
2291	Subsection (3), a parent's or guardian's use of medical cannabis or a cannabis product is
2292	not contrary to the best interests of a child if:
2293	(a) for a medical cannabis cardholder after January 1, 2021, the parent's or guardian's
2294	possession or use complies with Title 26B, Chapter 4, Part 2, Cannabinoid Research
2295	and Medical Cannabis, and there is no evidence that the parent's or guardian's use of
2296	medical cannabis unreasonably deviates from the directions of use and dosing
2297	guidelines determined by the parent's or guardian's [qualified medical provider]
2298	recommending medical provider or through a consultation described in Subsection
2299	26B-4-230(5); or
2300	(b) before January 1, 2021, the parent's or guardian's possession or use complies with
2301	Subsection 58-37-3.7(2) or (3).
2302	(5) Subsection (3) does not prohibit a finding of abuse or neglect of a child and Subsection
2303	(3) does not prohibit a finding that a parent's or guardian's use of medical cannabis or a
2304	cannabis product is contrary to the best interests of a child, if there is evidence showing
2305	a nexus between the parent's or guardian's use of cannabis or a cannabis product and

2306	behavior that would separately constitute abuse or neglect of the child
2307	Section 28. Effective Date.
2308	This hill takes effect on July 1, 2025